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ABSTRACT 
Chronic rhinosinusitis is one of the most common chronic respiratory tract diseases 
affecting up to 15% of the adult population in the Western world. It may be 
perpetuated by factors predisposing to sinus ostial obstruction together with 
inflammatory changes in the sinus mucosa. The significance of fungal and bacterial 
infections is doubtful. Chronic rhinosinusitis is regularly associated with asthma, 
and it is suggested to represent, at least in part, the same disease process. Chronic 
rhinosinusitis with nasal polyposis (CRSwNP) and asthma share also the 
characteristic inflammatory features and histopathologic feature of airway 
remodelling. Remodelling is considered as a key event in the pathogenesis of 
asthma. It is regarded to be controlled by a delicate balance between the matrix 
metalloproteinases (MMPs) and their regulators.  
The purpose of the present study was to evaluate the microbiological findings, 
inflammatory features and MMP and tissue inhibitor of metalloproteinases-1 
(TIMP-1) expression in CRSwNP. The results were related to the patient history, 
exposure to moisture and clinical outcome in order to find out possible 
explanations for the etiology and chronicity of CRSwNP. 
Bacterial culture results were similar in patients and in controls and do not explain 
the chronic course of CRSwNP. The presence of fungi seems to be more common 
in CRSwNP than chronic rhinosinusitis in general, and they should be actively 
searched for using microbiological as well as histological methods. Typical outdoor 
fungal species were found in nasal lavage samples taken from controls in the 
autumn but not in the winter, reflecting environmental exposure. Exposure to 
moisture was reported by 46% of the CRSwNP patients, which is in accordance to 
the Finnish general population. Exposed patients did not differ significantly from 
non-exposed subjects with regards to microbiological findings, tissue eosinophilia 
and clinical outcome.  
Significantly elevated levels of collagenase-2 (MMP-8) and interleukin (IL)-8 but 
not tumour necrosis factor-α were found in CRSwNP patients relative to controls. 
In particular, the activation of mesenchymal-type MMP-8 but not 
polymorphonuclear-type MMP-8 was associated with elevated IL-8 levels. IL-8 
and MMP-8 may form an inductive cytokine-proteinase cascade in CRSwNP 
pathogenesis and provide a target for novel therapies and an adjunctive diagnostic 
tool for monitoring CRSwNP treatment. The proteolytic spectrum is different in 
eosinophilic and non-eosinophilic CRSwNP with the up-regulation of MMP-8 and 
MMP-9 in non-eosinophilic CRSwNP, suggesting different pathophysiology in 
Abstract 10 
these subgroups. The lack of MMP up-regulation was associated with a poor 
prognostic factor and worse clinical outcome, representing a possible synergic anti-
inflammatory function of MMP-8 and MMP-9 in CRSwNP. 
This study provides new information about possible immunologic mechanisms in 
the pathogenesis of CRSwNP. The recently discovered anti-inflammatory/ 
defensive properties of MMP-8 and MMP-9 in animal models are reported for the 
first time in a clinical setting in human inflammatory diseases. 
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REVIEW OF THE LITERATURE 
1. Rhinosinusitis 
1.1. Definition and subclasses 
The Sinus and Allergy Health Partnership Task Force has defined rhinosinusitis as 
“a group of disorders characterized by inflammation of the mucosa of the nose and 
the paranasal sinuses”.23 This definition emphasizes that sinusitis is in general 
accompanied by concurrent inflammation of the nasal mucosa. Therefore, the term 
rhinosinusitis is recommended instead of the term sinusitis in both the European 
Academy of Allergology and Clinical Immunology position paper on rhinosinusitis 
and nasal polyps and the latest American rhinosinusitis classification.103,196  
The International Classification of Diseases divides rhinosinusitis into acute and 
chronic forms according to the duration of the symptoms. Acute rhinosinusitis lasts 
up to 12 weeks (four weeks in the American Rhinosinusitis Classification) with 
complete resolution of symptoms, whereas the chronic form persists beyond 12 
weeks.103,196 In immunocompetent persons viral rhinitis usually precedes acute 
rhinosinusitis and does not require antibiotics for the first seven to ten days unless 
complicating features are present. If symptoms do not begin to resolve in that time, 
bacteria are presumed to be involved. So, the current diagnostic clinical criteria for 
acute bacterial rhinosinusitis, and the indication for antimicrobial therapy as well, 
include a common cold that is no better after 10 days or worsening disease after 5 
to 10 days. The same symptom patterns are accepted also in research definitions for 
acute bacterial rhinosinusitis.103,196 
Chronic rhinosinusitis (CRS) is divided into two subclasses: CRS without nasal 
polyposis (Chronic RhinoSinusitis sine Nasal Polyposis, CRSsNP) and CRS with 
nasal polyposis (CRSwNP). This subclassification is supported by the fact that 
CRSsNP differs from the polypoid form in histologic factors, inflammatory profiles 
and clinical outcome, indicating possible different pathogenic processes involved in 
these subclasses.99 In the European position paper CRS is considered as a major 
finding and nasal polyposis represents a subgroup of this entity.103 From this 
definition it follows that nasal polyposis does not exist without concurrent chronic 
inflammation in the paranasal sinuses. The American consensus conference on 
rhinosinusitis differs from the European version also in CRS classification. They 
suggested a classification scheme for CRS based on the presence or absence of 
three distinguishing features: (1) nasal polyps; (2) eosinophilic or other 
inflammatory features; and (3) fungal hyphae in sinus mucus.196 This classification 
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also classifies possible different causative factors and is mainly intended for 
research purposes. For clinical use their recommendation was that the minimal 
classification would be either CRSsNP or CRSwNP. 
In addition, other classes are described in the medical literature, such as subacute 
rhinosinusitis (persisting 4-12 weeks), acute recurrent rhinosinusitis (over four 
episodes/year with resolution of symptoms between episodes), and acute 
exacerbation of chronic rhinosinusitis (persistent symptoms between episodes) in 
recognition of possible differing aetiologies and bacteriology, but the clinical 
relevance of these subclasses needs to be determined.175  
1.2. Epidemiology 
Rhinosinusitis constitutes one of the most common respiratory tract diseases.150,281 
In a common cold there are frequently abnormalities in the paranasal sinuses.118,254 
In a study of 31 young adults with early common cold these abnormalities were 
observed using computed tomography (CT) in the maxillary sinus in 87% of the 
patients, the ethmoid sinus in 65%, the frontal in 32%, and the sphenoid in 39%.118 
In majority of patients the abnormalities resolved within a few weeks without 
antimicrobial therapy indicating that the common cold is actually viral 
rhinosinusitis. Moreover, viral infection has been detected in over 80% of patients 
with common cold and radiological abnormalities in the paranasal sinuses.254 In 
immunocompetent patients with the common cold rhinovirus has been the major 
causative viral agent found in maxillary sinus aspirates, sinus brushing samples or 
mucosal biopsies in over 50% of patients.117,242,243,254 Other viruses detected from 
maxillary sinuses include coronavirus, influenza virus A and B, parainfluenza virus 
and adenovirus and in children also respiratory syncytial virus (RSV).143,188,254 
Further, RSV infection significantly enhances nontypeable Haemophilus influenzae 
attachment to respiratory epithelial cells, thus providing an example of mechanisms 
other than ostial obstruction by mucosal swelling by which viral infection results in 
secondary bacterial infection in acute rhinosinusitis.143 However, it is estimated that 
only 0.5-2% of acute viral rhinosinusitis develops into acute bacterial infection.150   
There are no large epidemiological studies on the prevalence of CRS in 
Scandinavia or Europe. In a review article an estimated prevalence of 14% in the 
United States was reported.150 The prevalence had increased by 50% from 1982 to 
1993 in the USA, when estimated by the number of restricted activity days per 
year, and a similar trend is also seen in the Finnish hospital material.63,302 In the 
Canadian cross-sectional study of over 73 000 subjects 12 years of age or older, 
conducted as a part of the National Population Health Survey, the prevalence of 
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self-reported CRS was 5%.56 It was higher in female (5.7%) than in male (3.4%) 
subjects. The prevalence increased with age, and the sex difference was consistent 
across age groups. In this study rhinosinusitis were assessed by positive answer to 
question “Do you have sinusitis diagnosed by a health professional?” Chronicity 
was defined as “long-term conditions” lasting or being expected to last 6 months or 
longer. CRS was associated with cigarette smoking, low income, allergy, asthma, 
and chronic obstructive pulmonary disease. The investigators concluded that the 
much lower prevalence of CRS among Canadians compared to the Americans may 
result from geographic differences, as the prevalence of reported rhinosinusitis in 
the north-eastern region of United States is approximately half that of the southern 
region.  
It is estimated that 20% of patients with chronic rhinosinusitis have also nasal 
polyposis.272 This seems a small proportion considering the reported prevalence of 
nasal polyps in Europe and the current conception of nasal polyposis being a 
subgroup of CRS. The prevalence of nasal polyposis was reported to be 4.3% in 
southern Finland in a postal questionnaire survey of a population-based random 
sample of 4300 subjects.133 This is in accordance with the 2.11% prevalence of 
nasal polyposis in the French general population, estimated by a large cross-
sectional, case control study using a validated questionnaire.163 Male predominance 
is often reported, although this was not seen in the French study, and the prevalence 
tends to increase with age.65,163 In the French study allergies were significantly 
more frequent among nasal polyposis patients. In contrast, in a study of 3000 atopic 
subjects, the prevalence of nasal polyps was 0.5%, and nasal polyposis is generally 
considered not to be an allergic condition.47 Up to over 50% of patients with 
CRSwNP have associated asthma, which is typically the non-atopic late-onset type 
and 30% to 40% also have aspirin (ASA) intolerance.272,281 In children younger 
than 10 years polyps are rare, and a possibility of cystic fibrosis should be 
considered in case of a child with nasal polyposis.281  
1.3. Causative factors 
Acute rhinosinusitis is usually an infectious process in which sinus ventilation and 
drainage are impaired as a consequence of a nasal infection, whereas chronic 
disease might result from a wide range of processes. Today CRS is acknowledged 
to be caused by a gradual obstruction due to increased tissue formation in the 
ostiomeatal complex, leading to impaired sinus ventilation and drainage.13 As a 
consequence the oxygen levels inside the sinus decrease, resulting in impaired 
phagosytosis by decreased opsonization of bacteria, which in turn leads to 
increased virulence of micro-organisms.157 Hypoxia can also enhance the 
production of proteolytic enzymes, which in turn decrease the mucociliary 
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clearance.157 These result in enhanced inflammatory and proteolytic reactions 
together with mucosal edema, and so further obstruct the ostiomeatal complex 
creating a vicious circle leading to chronic inflammatory disease. Besides the 
physical pathological mechanism, local and systemic factors predisposing to ostial 
blockade and infection together with inflammatory changes in the mucosa of the 
nasal cavity and paranasal sinuses eventually contribute significantly to the 
chronicity of rhinosinusitis.13,122 
1.3.1. Anatomical variations 
The significance of anatomical variations as a predisposing factor in CRS is 
controversial. The anatomical variants that may obstruct the ostiomeatal unit 
include deformities of the uncinate process, pneumatization or paradoxal curvature 
of the middle turbinate, bulla ethmoidalis, Haller’s cells and agger nasi cells.122 
However, the overall prevalence of anatomical variations possibly causing 
ostiomeatal narrowing has been about 40% both in CRS patients and control 
subjects.146 Some studies have reported higher prevalence of specific anatomical 
variations in CRS patients, for example concha bullosa in 29-33% of CRS patients 
compared to 11-16% in healthy subjects.46,146 Also accessory maxillary sinus ostia 
are found in approximately 30% of patients with CRS and in 10-20% of healthy 
subjects.144,146,152 This additional ostium may cause mucus to recirculate from the 
sinus to the nasal cavity through the natural ostium and back to the sinus through 
accessory ostium.152 Recirculating mucus can become recurrently infected. 
However, there has been no consistent difference in the prevalence of anatomical 
variations between a symptomatic group and a control group.146,156 
1.3.2. Microbial factors 
The role of viral and bacterial infections in the onset of CRS is not completely 
clarified.13,122 The microbiology of CRS differs from that in acute rhinosinusitis. 
The predominant bacteria in CRS are Staphylococcus aureus, coagulase negative 
staphylococci, Pseudomonas aeruginosa and anaerobic bacteria, alone or in 
combination with facultative aerobic and anaerobic bacteria, whereas Streptococcus 
pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are recovered 
from over 75% of patients with acute rhinosinusitis.102,119,209,326 However, their 
pathogenicity in CRS is largely unknown. The significance of fungal infections is 
equally uncertain. Fungal infections may have a more subtle onset and a more 
chronic course than bacterial rhinosinusitis, and it is estimated that 5-10% of CRS 
patients actually have fungal rhinosinusitis.110,190 However, a recent hypothesis that 
fungal colonization of the nose serves as major inflammatory stimulus in inducing 
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and sustaining eosinophilic inflammation in most CRS patients needs further 
studies, as the prevalence of fungal findings, as well as the fungal species 
recovered, was comparable in the patient and the control samples.32,45,246 Microbes 
may be implicated in the pathogenesis of CRS by other mechanisms than those 
causing persistent infection in the paranasal sinus mucosa, including bone 
involvement, bacterial biofilms and superantigens.  
1.3.2.1.  Osteitis 
Studies in both animals and humans show that the adjacent bone may become 
involved in the chronic inflammatory process with changes similar to those seen in 
chronic osteomyelitis.158,160,239 Moreover, the inflammation typically spread 
through the Haversian canals in the bone, resulting in bone changes at a distance 
from the site of the primary infection.239 In one study the ethmoid bone specimens, 
labelled prior to surgery with two short courses of oral tetracyclines two weeks 
apart, were collected from CRS patients undergoing sinus surgery and from 
patients operated on for non-inflammatory sinus disease.158 CRS patients were 
found to have significantly greater bone remodelling activity, demonstrated by 
significant separation of the two lines of fluorescence caused by tetracyclines, with 
histologic changes including new bone formation, fibrosis, and presence of 
inflammatory cells when compared to controls. The bone turnover in CRS patients 
was similar to that in osteomyelitis and trauma. Thus, an active inflammatory 
process occurring in the bone may be a factor in the changes seen in overlying 
mucosa and in the resistance of CRS to medical therapy.158,159  
1.3.2.2.  Bacterial biofilms 
Biofilms, which are communicating organizations of microbes surrounded by 
glycocalyx, could also explain the resistance of CRS to medical therapy. The vast 
majority of bacteria exist within a biofilm, including Pseudomonas aeruginosa, 
Hemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus, 
which are often found in association with otolaryngologic diseases.248 Bacterial 
biofilms have been documented on middle ear mucosa and cholesteatoma.247 There 
is also evidence of the presence of bacterial biofilms in a rabbit model of 
Pseudomonas aeruginosa rhinosinusitis and in patients infected with Pseudomonas 
aeruginosa who have symptomatic CRS despite medical and surgical 
treatment.72,240 Although antibiotic therapy and activated host defence mechanisms 
are able to kill planktonic cells derived from biofilms and often relieve symptoms, 
they cannot kill the bacteria in biofilms that constitute the foci of these chronic 
infections.70 Mechanical debridement is the only mechanism resolving biofilms, 
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which may explain the improvement of symptoms of CRS with surgery and 
irrigation. 
1.3.2.3.  Superantigens 
A number of micro-organisms produce exotoxins (also called enterotoxins) that are 
able to activate T lymphocytes by cross-linking the MHC (Major 
Histocompatibility Complex) II on antigen-presenting cells with the variable beta 
region of the T cell receptor on T cells.59,168 Both the MHC II molecule binding 
area and the T cell reseptor binding area for exotoxins are located distant from the 
antigen-specific binding region.266 Exotoxins are able to bind to several T cell 
receptor variable beta region gene motifs. This leads to activation of up to 30% of 
T lymphocytes, whereas classical antigens can activate less than 0.01% of T 
lymphocytes, thus the name superantigens.170 Superantigens can also act as 
classical antigens and anti-superantigen antibodies are often generated 
concomitantly. Common microbial superantigens include Staphylococcus aureus 
enterotoxin and some fungi, such as Alternaria and Aspergillus, may have 
superantigen activity.54,266 It is hypothesized that CRS patients, especially those 
with nasal polyposis, could have microbial superantigen production inside the 
paranasal sinuses with subsequent sinus mucosal immune activation leading to 
eosinophilic inflammation in genetically susceptible hosts.266 In fact, Bachert and 
colleagues demonstrated specific immunoglobulin (Ig)E to Staphylococcus aureus 
enterotoxins A and B in 50% of altogether 20 patients with eosinophilic nasal 
polyposis.12 Moreover, the presence of Staphylococcus aureus enterotoxin specific 
IgE was associated with higher levels of total serum IgE, more severe local disease 
and increased incidence of systemic manifestations such as asthma, suggesting a 
possible role of superantigens as disease modifiers. 
1.3.3. General host factors 
1.3.3.1. Allergy 
Allergic rhinitis may be a predisposing factor for rhinosinusitis as it may alter the 
normal physiology of the paranasal sinuses by obstructing the sinus ostia. Although 
its contribution in CRS is controversial, there is evidence that allergic rhinitis might 
facilitate development of acute bacterial rhinosinusitis.6,263 IgE-mediated rhinitis 
patients have been demonstrated to have more severe paranasal sinus changes in 
CT scans during a common cold than non-allergic subjects, indicating perhaps a 
greater risk for development of acute bacterial rhinosinusitis.6 In a Finnish study of 
224 patients with verified acute rhinosinusitis the incidence of allergy, confirmed 
Review of the Literature 17
by means of an allergy questionnaire, skin testing and nasal smears, was 25%.263 In 
addition, probable allergy was found in 6.5% of patients. In the control group the 
corresponding percentages were 16.5 and 3. However, allergic patients did not 
differ from non-allergic in the number of prior acute rhinosinusitis.  
Several studies have reported an increase in the prevalence of atopic markers and 
allergy in CRS patients.125,283,294 Approximately half of the CRS patients have 
associated allergies, and the prevalence of positive skin prick tests in patients 
undergoing sinus surgery has been over 80% in some studies.101,294 Controversially, 
the prevalence of CRSwNP was only 0.5% in atopic subjects compared to 4.5% 
prevalence in non-atopic patients.47,272 Moreover, nasal polyps are statistically more 
common in nonallergic asthma than in allergic asthma (13% vs. 5%).272 
Furthermore, the total IgE levels and concentration of eosinophilic cationic protein 
(ECP) and interleukin (IL)-5 in CRSwNS do not differ between atopic and non-
atopic subjects, indicating that the systemic allergic phenotype does not correlate 
with local inflammatory mechanisms leading to eosinophilic inflammation in the 
sinus mucosa.11,13,171,172 In CRSsNP the allergic patients have a full T helper cell 
(Th) type 2 cytokine profile compared to mixed Th1/Th2 cytokine pattern seen in 
non-allergic patients.125 Also the degree of eosinophilic infiltration is not markedly 
different between allergic and non–allergic subjects. Thus it seems that local 
immunological responses are more important in the development of inflammation 
in CRS than atopic status. 
1.3.3.2. Asthma and aspirin intolerance 
CRS is strongly associated with asthma. Approximately 80% of asthmatic patients 
have allergic rhinitis and 60% have rhinosinusitis.282 Conversely, up to over 50% of 
CRSwNP patients have asthma, of whom 30-40% have also ASA intolerance.272,283 
The incidence of rhinosinusitis as identified by radiography in ASA intolerant 
asthmatics may be over 95% and the frequency of nasal polyps may be as high as 
70%.169 The aspirin-exacerbated respiratory disease is a clinical syndrome defined 
as a triad of asthma, nasal polyposis and intolerance to ASA and most of the non-
steroidal anti-inflammatory drugs.24 The onset of the disease occurs typically in the 
early adulthood.24 The mechanism activating the underlying respiratory disease is 
unknown, but the pathogenesis of the respiratory reactions in this disease is in part 
due to altered archidonate metabolism.305 In Finland Hedman and colleagues 
examined the prevalence of ASA intolerance and its relation to doctor-diagnosed 
asthma as a part of a postal questionnaire survey studying the prevalence of asthma 
in adults.133 The prevalence of ASA intolerance causing attacks of asthma was 
1.2%. It was significantly higher in patients with doctor-diagnosed asthma than 
without (8.8% versus 0.8%). 
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1.3.3.3.  Immunodeficiency 
A global deficiency of all immunoglobulins (congenital or acquired 
hypogammaglobulinemia) is associated with increased susceptibility to recurrent 
pyogenic infections, including rhinosinusitis.327 In addition, IgA deficiency, which 
is the most common Ig deficiency occurring in 1 of 700 individuals, can lead to 
recurrent sinopulmonary infections, especially in association with a deficiency in 
IgG2, or other IgG subclasses.229,327 The high incidence of immune dysfunctions 
was found in a retrospective study of 79 patients with refractory rhinosinusitis 
referred to the Allergy and Immunology Clinic for immunological evaluation.55 
Abnormalities of T cell function, estimated by in vitro testing of T cell response to 
recall antigens, alloantigens and T cell mitogens, were the most common defects 
found in over 50% of 60 patients who underwent the tests. Moreover, 17.9% of 
patients had low IgG levels, 16.7% had low IgA and 6.2% had low IgM, and 
common variable immunodeficiency was diagnosed in 9.9%. The high incidence of 
immune dysfunctions may be explained partly by patient selection, since patients in 
this study were referral patients from an otorhinolaryngology clinic to an 
immunology clinic, and thus were already suspected to have possible immune 
defects. However, similar numbers of immunodeficiency were found in patients 
with CRS or recurrent rhinosinusitis in a London clinic.265 Of 74 adult patients, 14 
subjects (19%) had low levels of one of the major Ig classes and 23 subjects (31%) 
had one or more IgG subclass deficiencies. High incidence of Ig deficiency was 
also found by May and colleagues, who evaluated 245 patients with CRS refractory 
to prolonged antibiotic treatment.194 In their study five patients (2.0%) had common 
variable immunodeficiency and 17 patients (6.9%) had an IgG subclass deficiency. 
Also acquired immunodeficiency syndrome patients are reported to have an 
increased occurrence of rhinosinusitis, as well as an increased incidence of features 
predisposing to rhinosinusitis, such as chronic mucosal thickening and decreased 
mucociliary clearance.198,232 
1.3.3.4.  Ciliary dysfunction 
Decreased mucociliary clearance is considered to be one of the key elements 
contributing to rhinosinusitis chronicity.13,122,157,327 Thus diseases affecting ciliary 
function frequently associate with chronic rhinosinusitis. Primary ciliary dyskinesia 
is a recessively inherited group of disorders of ciliary structure and/or function 
resulting in recurrent or chronic respiratory tract infections with mucus retention 
leading to rhinosinusitis, serous otitis media, rhinitis, and bronchitis.217 It is a rare 
disorder with an incidence of 1 in 15000 in the white population. However, in 
children with recurrent respiratory diseases, primary ciliary dyskinesia can be 
found in approximately 5%.52 Kartagener's syndrome, a triad of bronchiectasis, 
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rhinosinusitis, and situs inversus, is found in 50% of primary ciliary dyskinesia 
patients.58 Diagnosis relies on clinical evaluation and electron microscopic analysis 
of ciliary ultrastructure.217 
1.3.3.5. Other associated diseases 
Another congenital disorder associated with CRSwNP is cystic fibrosis.178 Nearly 
every patient with cystic fibrosis has paranasal sinus involvement, but the disease is 
rare in Finland.140 However, it should be considered in children and teenagers, who 
develop nasal polyposis, and also in adult patients, who are operated on for chronic 
rhinosinusitis when younger than 18 years.272 Interestingly, in the United States the 
cystic fibrosis gene mutations have been found to be significantly more common in 
CRS patients than in controls (7% vs. 2%), even after exclusion of undiagnosed 
cystic fibrosis patients, suggesting that mutations in genes responsible with cystic 
fibrosis could promote the development of CRS in the general population.333 
However, the higher prevalence of cystic fibrosis gene mutations was not seen in 
Finnish CRS patients, reflecting perhaps the low prevalence of these mutations in 
the Finnish population.140 Paranasal sinus and nasal cavity involvement is also a 
common feature in chronic granulomatous disorders, including Wegener’s 
granulomatosis, Churg-Strauss syndrome and rare cases of the paranasal sinus 
sarcoidosis.85,113,138 
1.3.4. Other factors  
Maxillary rhinosinusitis may also have a dental origin. Periapical abscess or the 
placement of dental implants in the upper jaw may result in secondary 
rhinosinusitis with the characteristic features of unilateral disease caused by typical 
oral pathogens, mainly anaerobes.36 Also dental obturating material may enter into 
the sinus and cause chronic infection.36 Perhaps the most common, and probably 
most frequently unrecognised, odontogenic cause resulting in radiologic finding 
consistent with CRS, including sinus mucosal thickening, air-fluid levels in the 
sinus or complete opacification, is periodontal disease.1 Sixty % of patients with 
periodontal disease have been found to have sinus involvement in CT scans 
compared with 29% of an age-and-sex-matched control population.1 An even 
higher incidence of maxillary sinus changes was seen in a small study of 13 
patients with advanced periodontal disease.96 As many as 79% of the patients 
showed swelling of the mucosa prior to periodontal therapy, compared to only 17% 
after periodontal therapy.  
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Secondary rhinosinusitis may also develop due to a foreign body in the nasal cavity 
mainly in children and mentally handicapped subjects. In adults, nosocomial 
rhinosinusitis is a complication of critically ill patients needing prolonged 
intubation.295 Approximately 25% of patients intubated for 5 days or longer 
develop rhinosinusitis, and it is more common in patients with nasotracheal tubes 
than orotracheal tubes.227 Other risk factors for nosocomial rhinosinusitis are facial 
trauma, inability to mobilize the patient and prior sinus disease.295 
Environmental pollution, both outdoor and indoor, may cause irritation of the 
respiratory mucosa and, in the case of continuous exposure, perhaps also chronic 
inflammatory disorders of the respiratory tract, including nasal passages. In a 
German study a weak but consistent statistical association was found between the 
prevalence of CRS and above average air pollution, estimated by sulphur dioxide, 
nitrogen oxides and total suspended particles levels.343 Also ozone is known to 
cause increased respiratory symptoms and susceptibility to bacterial respiratory 
infections by inducing inflammatory response and respiratory epithelial damage, 
including decreases in mucociliary clearance.215 Oxidant pollutants are able to 
enhance the generation of proinflammatory cytokines by rhinovirus 16 -infected 
cells and thus suggest that virus-induced inflammation in upper and lower airways 
may be exacerbated by concurrent oxidant pollutant exposure.293 Smoking can 
cause ciliary loss and cytologic changes in the nasal mucosa, and thus act as a 
predisposing factor for CRS. In the Third National Health and Nutrition 
Examination Survey conducted in the United States 1988-1994, direct use of 
tobacco, but not passive tobacco smoke exposure, was associated with increased 
prevalence of acute and chronic rhinosinusitis.186 Smoking is also shown to 
increase the risk of recurrent disease following sinus surgery and the risk for 
reoperations.35,269 
1.4. Lower airway involvement in chronic rhinosinusitis 
In recent years there has been a growing understanding of the interactions between 
upper and lower respiratory tract. The nasal airways, the sinus cavities, and lower 
airways form a continuous structure lined with ciliated columnar epithelium and 
share a common embryologic origin. There are also several clinical observations 
supporting this so called integrated airway syndrome model, which has a wide 
spectrum of severity varying from rhinitis to asthma and possibly 
rhinosinusitis.308,322 Both allergic and non-allergic rhinitis are risk factors for 
asthma and also for acute exacerbations of asthma.112,184,273 Epidemiological studies 
indicate that rhinitis co-exists with asthma in 85% to 94% of patients, compared to 
approximately 20% in general population.309,322 Moreover, rhinitis in asthmatic 
patients is often more severe than in non-asthmatic patients. Several studies have 
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demonstrated that the severity of asthma correlates with the severity of rhinitis, and 
treatment of allergic rhinitis with topical corticosteroids or second generation 
antihistamines has beneficial effects on the outcome of asthma.66,104,121,273 
Furthermore, the lack of symptoms in the lower airways in rhinitis patients or the 
nasal cavity in asthmatic patients does not mean a lack of involvement. Allergic 
rhinitis patients with no history of lower airway symptoms have been found to have 
hyperresponsiveness, inflammation and even tissue remodelling in the lower 
airways.89,310 And vice versa, the nasal mucosa of the asthmatic patients shows 
signs of inflammation even in the absence of nasal symptoms.280 
Rhinosinusitis is less clearly related to asthma than rhinitis, but the data point to a 
similar relationship. The paranasal sinus abnormalities in CT examination are 
found in most patients with moderate to severe asthma, but radiological studies 
may be misleading since a high percentage of paranasal sinus abnormalities are 
found in allergic rhinitis also.34,208 Eosinophilia in the sinus mucosa is stronger in 
patients with rhinosinusitis and asthma when compared to those with rhinosinusitis 
alone.129 Also corresponding histopathologic features of epithelial remodelling, 
including epithelial erosion and basement membrane thickening, have been seen in 
sinonasal specimen from chronic rhinosinusitis patients and in asthmatic bronchial 
mucosal specimens suggesting that CRS and asthma are part of the same disease 
process.30,245  Moreover, medical and surgical treatment of CRS have been reported 
to improve asthma outcomes, estimated by asthma severity, frequency of asthma 
attacks and need for medication.43,270,282 However, no firm conclusions can be 
drawn from these studies with the exception of CRSwNP associated with asthma in 
aspirin-exacerbated-respiratory disease.24 
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2. Chronic rhinosinusitis with nasal polyposis 
2.1. Diagnosis 
The lack of pathognomonic symptoms makes objective measurements necessary to 
accurately diagnose rhinosinusitis. Anterior rhinoscopy is the basic tool to 
determine pathology existing in the sinonasal passages. During examination 
attention is paid to possible mucosal edema and/or erythema, polyps or polypoid 
swelling, crusting, and nasal discharge. Decongestion with topical decongestants is 
recommended to achieve better visibility to the middle turbinates. Despite the use 
of decongestants the middle meatus and posterior parts of the nasal cavity stay 
poorly visualized unless nasal endoscopy is included in the physical examination. 
Besides research purposes nasal endoscopy during an office evaluation is indicated 
in patients, who have unilateral disease without septal deviation, who have severe 
and disabling symptoms, who are immunocompromiced, or after sinus surgery or 
trauma.196    
The imaging studies are necessary in assessment of the extent of inflammatory 
changes within the various sinuses and in defining the anatomy of the sinuses 
before surgery. It is also indicated if complications are suspected. The modality of 
choice in sinus imaging is CT, as it gives good resolution of the regional anatomy 
of the bony structures and mucosa.103,196 However, the diagnosis of CRS should not 
be based on CT findings alone, as the prevalence of incidental mucosal changes in 
an asymptomatic population is approximately 30%, or even higher in the paediatric 
population.146,183 Magnetic resonance imaging is superior to CT in differentiating 
between inflammatory disease and fungal concretions, although rarely used in this 
indication in Finland, and in establishing the presence of neoplasia. It is also 
indicated if intracranial complication is suspected. 
The research criteria for diagnosis of CRSwNP include: (1) two or more of the 
following symptoms: anterior and/or posterior mucopurulent drainage; nasal 
obstruction; facial pressure or pain; and decreased sense of smell persisting beyond 
12 weeks, (2) the presence of nasal polyps confirmed in nasal endoscopy; and (3) 
CT imaging with mucosal changes within ostiomeatal complex and/or sinuses.103,196 
After sinus surgery the presence of polyps is defined as pedunculated lesions on 
endoscopic examination over six months past operation. For clinical use the 
requirements for objective documentations are alleviated. Anterior rhinoscopy after 
nasal decongestation is sufficient to record the absence or presence of polyps. Also 
sinus CT imaging is optional, although strongly recommended. The differential 
diagnosis includes antro-choanal polyp; congenital abnormalities, such as 
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meningocele and meningoencephalocele; benign tumours, such as papilloma and 
meningeoma; and malignant tumours.13 These should be suspected especially in 
case of unilateral disease, but a biopsy of the polyp tissue should always be taken 
when new nasal polyps are found. Also possible underlying causes, such as aspirin-
exacerbated respiratory disease, cystic fibrosis, primary ciliary dyskinesia or 
paranasal sinus fungal infection, need to be considered in establishing CRSwNP 
diagnosis.13,122,272 
2.2. Histology 
Histologically CRSwNP differs distinctly from the normal nasal mucosa as well as 
from CRSsNP. The major histologic hallmark of CRSwNP is eosinophilic 
inflammation of the mucosa with the exception of nasal polyposis in association 
with cystic fibrosis and primary ciliary dyskinesia, in which there are lymphocytes 
in the tissue and neutrophil leucocytes in the secretions.207,285 The common 
histomorphologic feature in both types of CRS is thickened basement membrane. 
CRSsNP is characterized by goblet cell hyperplasia, prominent fibrosis and limited 
subepithelial edema, whereas in polyp tissue there are areas of squamous cell 
metaplasia surrounded by normal ciliated columnar epithelia and the stroma is 
edematous and sometimes fibrotic with a reduced number of goblet cells and 
submucosal glands.207 The structure of submucosal glands is also abnormal in 
CRSwNP, showing signs of cystic degeneration with stagnation of mucus within 
the distended tubules.207 The sensory nerves and the autonomic vasomotor and 
secretory nerves found in normal as well as abnormal nasal mucosa are not seen 
within the polyp stroma, and the vascularity is sparse.51 The formation of 
pseudocysts is characteristic to polyps even in the early stage of polyposis.11 In 
pseudocysts there are activated eosinophils and myofibroplasts together with 
depositions of fibronectin, albumin and probably other plasma proteins in the 
luminal compartment of the polyps, suggesting a central deposition of plasma 
proteins as a principle pathogenic mechanism of polyp formation and growth.11 It is 
not known why the extravasated plasma is captured inside the stroma and not 
escaping to the airway surface. The suggested explanations include distance, 
binding forces, and extracellular matrix damage or abnormality. 
There is also evidence of tissue remodelling in nasal polyp tissue. Remodelling is a 
dynamic process that involves extracellular matrix production and degradation in 
reaction to different stimuli leading to a normal reconstruction process or a 
pathologic one. Airway remodelling, together with chronic mucosal inflammation, 
is a key event in development of asthma involving subepithelial basement 
membrane thickening, epithelial damage (shedding), smooth muscle hypertrophy, 
deposition of fibrillar collagen and elastic fibre disruption.30 Basement membrane 
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thickening, subepithelial collagen deposition and epithelial shedding have also been 
demonstrated in CRSwNP.245,284 The extracellular matrix accumulation has been 
speculated to be behind the polyp formation and growth in the experimental 
models.219 In fact, increased depositions of collagen types III and V, and to a lesser 
degree collagen I, are found in nasal polyps compared to control nasal turbinate 
tissue supporting this experimental theory.204 Fibroblastic cells, including 
fibroblasts and myofibroblasts, which are the cellular source of extracellular matrix 
proteins, are abundant in nasal polyps, particularly in the pedicle area, but are not 
found in the normal nasal mucosa, giving further evidence for the extracellular 
matrix theory.332 Moreover, the products of activated eosinophils found in 
increased numbers in CRSwNP are probably able to stimulate fibroblastic cell 
mediated collagen deposition.284,300 
2.3. Inflammatory features 
In CRSsNP the inflammatory cells in sinus fluid are predominantly neutrophils, 
whereas in CRSwNP eosinophils predominate.13 The presence of eosinophilic 
inflammation in 263 patients operated on for nasal polyposis and 31 patients 
operated for non-polypoid CRS was analysed in a retrospective study.142 All 
patients with CRSsNP had less than 10% eosinophils with an overall mean of 2%, 
whereas nearly 90% of samples from CRSwNP patients showed more than 10% of 
eosinophils and the overall mean was 50%. Similar numbers were found in another 
study, in which over 70% of CRSwNP patients had eosinophilic inflammation with 
expression of EG2 (a monoclonal antibody against the secreted form of ECP) 
activation marker of eosinophils in the majority of eosinophil-positive samples.300 
Allergic and non-allergic CRSwNP patients do not differ in the degree of 
eosinophilic inflammation.142 There is also a mild increase in the number of plasma 
cells and mast cells and evidence of mast cell degranulation in CRSwNP.154 Mast 
cells play a key role in IgE-mediated diseases, such as allergic rhinitis, but are also 
involved in non IgE-mediated inflammatory diseases. Mast cells can express a 
variety of cytokines, which contribute to eosinophilic inflammation and some are 
also able to up-regulate chemokines, such as RANTES (Regulated on ActivatioN, 
T cell Expressed and Secreted), and thus further perpetuate the accumulation of 
eosinophils. The numbers of macrophages, neutrophils and CD (Cluster of 
Differentation) 8+ T-lymphocytes are normal, and the number of CD4+ T-
lymphocytes may be mildly increased.196 
Several cytokines and chemokines are reported to be up-regulated in CRSwNP. 
The cytokine profile is a mixed Th1/Th2 profile with more characteristic Th2 
cytokine profile in allergic patients.123,125 Increased numbers of the Th2-type 
cytokines IL-3, IL-4, IL-5, IL-13, and granulocyte/macrophage colony stimulating 
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factor (GM-CSF) and Th1 cytokine interferon (IFN)-γ have been demonstrated in 
CRSwNP.11,60,79,126,222 Also pro-inflammatory cytokines tumour necrosis factor 
(TNF)-α and IL-1β as well as profibrotic cytokines IL-11 and IL-17 are 
overexpressed in nasal polyps.11,68,124,204. In addition, C-X-C-chemokine IL-8 and 
C-C-chemokines RANTES and eotaxin are overproduced in CRSwNP.11,31,80 It is 
not known if IL-8 expression is actually dysregulated in CRSwNP, or does it rather 
represent the innate immunity response to sinus infection. The latter is supported by 
the finding of IL-6, IL-8, and IL-11 in both non-polypoid and polypoid CRS, and 
are thus probably nonspecific mediators of inflammation.31 Some growth factors, 
including transforming growth factor (TGF)-α, TGF-β and platelet derived growth 
factor that most likely induce myofibroblast development and thus contribute to the 
remodelling process, have been found in polyp tissue.332 Vascular endothelial 
growth factor, which is important for inducing angiogenesis and edema, is also 
increased in nasal polyps and its expression is further upregulated by TGF-β.69 In 
addition to cytokines and chemokines, enhanced levels of other inflammatory 
mediators, such as histamine and tryptase, and immunoglobulins IgA, IgE, IgG and 
IgM have been found in CRSwNP.196,235 
2.4. Pathophysiology 
2.4.1. Mechanisms 
CRSwNP is a multifactorial disease which is associated with miscellaneous 
diseases including asthma, ASA intolerance, cystic fibrosis and primary ciliary 
dyskinesia, but affect also otherwise healthy individuals.13,122,272,281 The 
inflammatory features of nasal polyps vary in different underlying diseases, thus 
further pointing to various mechanisms leading to polyp formation.207,285 The 
pathophysiological mechanisms of CRSwNP are poorly understood. Several 
hypotheses have been put forward as the underlying mechanisms of nasal 
polyposis. The basic problem with all theories is that they cannot explain why 
polyp formation occurs mainly in one particular area of a few square centimetres in 
the middle meatus and around the paranasal sinus ostia, although the nasal mucosa 
is usually universally inflamed. Moreover, these theories do not provide a sufficient 
explanation of the initiating factor causing the postulated processes. It is as well 
difficult to distinguish between the cause and consequence of the observed 
histologic alterations.  
The epithelial rupture theory is based on the concept that mucosal oedema, caused 
by for example allergy or infection, results in rupture of the epithelium.172 This is 
followed by a prolapse of the lamina propria through the epithelial defect and 
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epithelialization of the prolapsed tissue by proliferation and migration of epithelial 
cells from the surrounding epithelium, resulting in the gradual formation of small 
polyps. Polyp growth is then further augmented by gravitational effects and/or 
obstruction of venous drainage in polyp tissue. The vasomotor-imbalance thesis is 
based on the poorly vascularized stroma of nasal polyps, which lacks a 
vasoconstrictory innervation.172 The impaired vascular regulation could lead to 
increased vascular permeability and reduced detoxification of mast cell products. 
The prolonged effects of these substances, such as histamine, within the polyp 
stroma then result in tissue edema. Alterations of the bioelectricity of sodium 
channels have been found in the nasal mucosa indicating that sodium absorption 
may be increased in the stroma, which could lead to water retention in the 
epithelium and the lamina propria of polyps.26 Moreover, turbulent flow of air in 
the lateral wall of the nose or pollutant-viral-bacterial-host interactions has been 
proposed to produce inflammatory changes in the lateral wall of the nose.221 
However, since the increased level of several inflammatory mediators is a 
prominent feature in nasal polyps, chronic persistent inflammation is undoubtedly a 
key event in CRSwNP irrespective of the etiology. 
2.4.2. Role of eosinophils 
Tissue eosinophilia, resulting from increased transendothelial migration and the 
inhibition of apoptosis of eosinophils, is generally considered to be the main 
pathogenic event in the development of CRSwNP.13,129 Eosinophils are able to 
damage directly the epithelium of the respiratory tract by releasing toxin granule 
proteins.172 These granule proteins include ECP, major basic protein, platelet 
activating factor and eosinophilic peroxidases among others, and can result in 
ciliary loss, epithelial injury, and nerve damage in the nasal mucosa and thus 
eventually predispose to chronic inflammation.76,172 Several pathologic processes 
probably act in concert by promoting development of eosinophilic inflammation in 
CRSwNP. The pivotal factor in the pathogenic cascade is considered to be IL-5, 
since it has several effects on eosinophils.14,172,339 These effects include 
differentiation and proliferation factors, chemotactic properties, induction of 
adhesion molecules increasing recruitment of eosinophils into the tissue, and anti-
apoptotic effects.171,172,279 Furthermore, eosinophils are the only human leukocytes 
expressing receptors specific for IL-5.94  
Other processes, which might promote eosinophil accumulation, include local 
production of IL-3 and GM-CSF, which are able to up-regulate endothelial cell 
adhesion molecules, including vascular cell adhesion molecule (VCAM)-1, and to 
cause eosinophil activation and prolonged survival.123,126,200 Dysregulation of C-C–
chemokines RANTES and eotaxin in epithelium and nasal fibroblasts enhance the 
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local chemotaxis of eosinophils.123,200 Finally, TNF-α, IL-1 and IL-13 may 
contribute to the expression of VCAM-1, which selectively mediates the migration 
of eosinophils and mononuclear cells from the peripheral circulation into the 
tissues.172 IL-13 may further enhance IL-5 and eotaxin function.14,124 Eosinophils in 
nasal polyp tissue are also able to synthesize IL-3, IL-5, GM-CSF and TNF-α, and 
thus initiate an autocrine inflammatory mechanism potentially responsible for the 
persistent inflammation.14,68,279 
However, the driving force for eosinophil accumulation in CRSwNP is unknown. 
Moreover, the eosinophil accumulation itself does not explain development of 
asthma, a disease closely related to CRSwNP, as other clinical conditions with 
airway eosinophilia, for example eosinophilic pneumonia or sputum eosinophilia in 
patients with Crohn disease, are not associated with airway hyperresponsiveness 
and asthma symptoms.88 For asthma to develop and persist, the airway mucosa 
must also be susceptible to damage by chronic inflammation. Recent studies 
suggest that alterations in functions at the epithelial level, with inflammatory cells 
interacting with epithelial cells, are pivotal in remodelling processes in the 
pathogenesis of asthma, and a similar relationship may be involved also in 
CRSwNP.139  
2.4.3. Dysregulation of epithelium  
The microenvironmental theory of lateral nasal airway inflammation is based on 
increased release of several cytokines by the resident structural cells such as 
epithelial cells and fibroblasts.276 These cells are able to produce a number of 
cytokines, including TNF-α, IL-4, IL-5, IL-6, IL-8, and GM-CSF, which attract 
inflammatory cells and prolong their survival.14,207,276,344 In turn these inflammatory 
cells can produce cytokines such as IL-3, IL-5, TNF-α, and GM-CSF in an 
autocrine up-regulated fashion and recruit more inflammatory cells.14,68,279 The 
damaging effects of eosinophil-derived proteins and mediators on the sinus 
epithelium may further stimulate the cytokine production. There is also increased 
expression of intercellular adhesion molecule (ICAM)-1, VCAM-1, and P-selectin 
in the nasal polyp endothelium and C-C chemokines in the polyp epithelium and 
submucosal fibroblasts, all of which promote accumulation of 
eosinophils.22,124,231,304 
The epithelial functions have been studied extensively in asthma.57,139 In the 
bronchial mucosa epithelial cells form a so called epithelial-mesenchymal unit with 
mesenchymal cells located underneath the basement membrane, such as fibroblasts 
and myofibroblasts.57,139 This epithelial-mesenchymal unit controls tissue growth 
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during development and wound repair as well as inflammation by producing a wide 
range of proliferative and profibrotic growth factors. Profibrotic mediators directly 
regulate the mesenchymal cells to produce collagens, reticular and elastic fibres 
and proteoglycans.57,92 As the same process probably contributes to the basement 
membrane thickening and collagen deposition seen in asthmatic bronchial mucosa, 
it is supposed that dysregulation of epithelial-mesenchymal interactions might be 
involved in the pathogenesis of asthma. This could lead to impaired injury-repair 
cycle, blocking the epithelial cells in the “repair phenotype” with continuous 
release of growth factors and profibrotic mediators.57 There is also evidence, that 
Th2 cytokines, especially IL-4 and IL-13, stimulate expression of RANTES, 
eotaxin, IL-6, ICAM-1 and VCAM-1 in fibroblasts, and thus may influence 
properties of the epithelial-mesenchymal unit that are relevant to the asthmatic 
phenotype.90,139 Taking into consideration the similar inflammatory features and 
tissue remodelling changes in CRSwNP and asthma together with their clinical co-
existence, it is possible that a similar type of dysregulation of epithelium is also 
present in CRSwNP. 
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3. Bacteria in rhinosinusitis 
3.1. Normal nasal flora 
Although the paranasal sinuses are thought to be sterile under normal conditions, 
the nasal cavity and nasopharynx are colonized with normal flora.117, 149 The normal 
nasal flora in adults includes coagulase-negative staphylococci, Staphylococcus 
aureus and Corynebacterium species.147,264 Other aerobic bacteria, including 
Streptococcus viridans, Neisseria meningitis, enteric bacteria and Moraxella 
species have been isolated occasionally.147,264 With the exception of Staphylococcus 
aureus, the potentially pathogenic bacteria are rarely found from the nasal cavities 
in healthy adults. Controversially, in children also potentially pathogenic bacteria 
are frequently cultured from the nasal cavity, such as Streptococcus pneumoniae in 
10-52% of nasal swap samples from pre-school children, Haemophilus influenzae 
in 7-65% and Moraxella catarrhalis in 15-58%.115 Anaerobic bacteria, mainly 
Propionibacterium acnes, Peptostreptococcus species and Bacteroides species are 
found in up to 100% of healthy noses.147,264 In a small study of 12 healthy adults 
undergoing septoplasty, aerobic bacteria were recovered in sinus aspiration samples 
from seven and anaerobic bacteria from all twelve subjects, questioning the sterility 
of sinus cavities.39 The predominant anaerobic isolates were Bacteroides species, 
anaerobic gram-positive cocci and Fusobacterium species and aerobic isolates were 
beta β-haemolytic streptococci and α-haemolytic streptococci.   
The normal nasal flora has a clear impact on the occurrence of infections in other 
anatomical location and perhaps also in the sinuses.  Staphylococcus aureus is 
considered as the most important potentially pathogenic bacteria in the nasal 
cavity.107 Approximately 20% of healthy individuals carry Staphylococcus aureus 
consistently in the nose, and an even larger proportion, approximately 60%, has 
nasal colonization intermittently.164 Nasal carriage of Staphylococcus aureus is a 
risk factor for the development of wound infections after surgery; infections 
associated with haemodialysis, peritoneal dialysis; and possibly also bacteremia 
caused by an intravascular device in the intensive care settings.164 In the majority of 
infections the strains isolated from the site of infection have been identical to 
strains isolated earlier from the carriage site implicating endogenous infection. The 
significance of nasal carriage of Staphylococcus aureus was further demonstrated 
in a randomized, double-blind, placebo-controlled study of 3864 patients 
undergoing general, gynecologic, neurologic, or cardiothoracic surgery.238 The 
prophylactic intranasal application of mupirocin for 5 days prior to the operation 
did not significantly reduce the rate of Staphylococcus aureus surgical-site 
infections overall (2.3% in the mupirocin group vs. 2.4% in the placebo group), but 
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it decreased significantly the rate of Staphylococcus aureus infections among the 
patients who were Staphylococcus aureus carriers (4.0% vs. 7.7%, respectively).  
Other normal nasal flora bacteria, which may become primary pathogens, include 
Neisseria meningitis and group A streptococci. Meningococci are usually 
commensal bacteria in humans and only a minority of the nasopharyngeal isolates 
cause invasive disease.296 However, in populations living in confined areas such as 
military recruits, the rates of transmission and carriage are much higher, increasing 
also a risk of endogenous invasive meningococcal infection. Group A streptococci 
has been recovered from the throats of 21% of the 136 children who had a clinical 
and radiographic diagnosis of acute bacterial rhinosinusitis with symptoms lasting 
for a minimum 10 days and no complaints of sore throat as a prominent condition, 
whereas the carriage rate in asymptomatic children in the same community during 
the same season was 5.5%.328 The authors concluded that a streptococcal infection 
rather than a viral upper respiratory infection initiated the mucosal inflammation, 
which led to obstruction of the sinus ostia and a secondary purulent rhinosinusitis. 
3.2. Acute rhinosinusitis 
It is estimated that only 0.5% to 2.0% of cases of viral rhinosinusitis are 
complicated by secondary bacterial infection.150 In general, a sinus infection is 
caused by a single bacterial isolate in high density but in 25% two bacterial species, 
both in high density, are recovered.326 The most important bacterial causes of acute 
community-acquired rhinosinusitis are Streptococcus pneumoniae, Haemophilus 
influenzae and especially in children Moraxella catarrhalis.119,326 In the United 
States Gwaltney and colleagues summarized the results from several studies from 
1975-1990 concerning the microbiology of acute maxillary rhinosinusitis in 
adults.119 In maxillary sinus aspirates the most common bacteria were 
Streptococcus pneumoniae and Haemophilus influenzae, which accounted for 41% 
and 35% of the bacterial isolates, respectively. Next in frequency were streptococci 
other than pneumococci in 7%. In this study Moraxella catarrhalis was found in 
4% of patients, whereas in studies conducted in children its prevalence has been 
approximately 15-20%.326 The microbiology of acute frontal sinusitis is similar to 
that of acute maxillary rhinosinusitis, whereas in one study evaluating the 
microbiology of acute sphenoid sinusitis Streptococcus species and Staphylococcus 
aureus were the most dominant isolates in equal prevalence.37,259 Otherwise 
Staphylococcus aureus is an uncommon cause of acute rhinosinusitis both in adults 
and in children but it may cause serious complications such as intracranial 
infections and subperiosteal or orbital abscesses.326 Anaerobic bacteria have been 
isolated from approximately 5% to 10% of patients with acute rhinosinusitis.119 
Their presence in sinus mucus may indicate primary dental pathology. 
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The pathogens in nosocomial acute rhinosinusitis differ significantly from those in 
community acquired disease. Nosocomial rhinosinusitis usually develops in 
patients requiring extended periods of intensive care involving prolonged 
endotracheal or nasogastric intubation.10,227 The etiology is usually polymicrobial 
with about one-third being Gram-positive organisms, most often Staphylococcus 
aureus, and two thirds Gram-negative, predominating organism being 
Pseudomonas aeruginosa.295 The other typical pathogens include Klebsiella 
pneumoniae, Proteus mirabilis, Serratia marcescens, and Enterobacter species and 
anaerobes, such as Prevotella and Fusobacterum species.176,295 
Immunocompromised patients with acute rhinosinusitis may also present with 
atypical causative bacterial agents depending on the type of immunodeficiency and 
the time of the infection, highlighting the importance of bacterial cultures in the 
treatment of these patients.  
3.3. Chronic rhinosinusitis 
The significance of micro-organisms in CRS is less clear. Staphylococcus aureus, 
coagulase-negative staphylococci, gram-negative bacteria and respiratory 
anaerobes predominate in CRS, but it is difficult to interpret their meaning in the 
development of CRS.38,102,326 Coagulase negative staphylococci are recovered in 
about 40% of patients with CRS, but also in 35% of nasal samples taken 
endoscopically from the middle meatus in healthy individuals, and probably have 
no role in the pathogenesis of CRS.98 Correspondingly, Staphylococcus aureus has 
been reported to occur at similar rates in patients and control subjects.209 However, 
Staphylococcus aureus grew heavily from patient samples, whereas only light 
growth was seen in controls. Gram negative rods like Pseudomonas aeruginosa, 
Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, and Escherichia 
coli, which are rarely cultured from samples obtained from healthy individuals or 
from patients with acute community-acquired rhinosinusitis, are frequently reported 
in association with CRS.38,209,326,327 In a study performed in patients with severe 
CRS, the incidence of gram-negative isolates in samples taken from the middle 
meatus was 27%, of which over half were Pseudomonas.209 These organisms may 
be causative, or they might secondarily infect or colonize the altered environment 
in the sinuses. The latter is supported by the higher incidence of gram-negative 
rods, especially Pseudomonas aeruginosa in surgically treated sinuses than in 
sinuses not surgically treated, reflecting most likely the change in the sinus 
microenvironment.  
The reported prevalence of anaerobes in sinus aspirates from CRS patients varies 
from as high as 80-100% in some studies to 0-25% in others, reflecting most likely 
the technical differences in specimen handling.122 The predominant anaerobes 
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isolated in CRS include anaerobic streptococci, Prevotella species and 
Fusobacterium.38,102,326 Recurrences of signs or symptoms of bacterial maxillary 
rhinosinusitis have been reported to associate twice as often with anaerobes 
compared to aerobes when bacteria counts were over 103 colony forming units/mL, 
thus implicating their possible role in the disease chronicity.102 In one study the 
microbiology of sinus aspirates was studied in patients who failed to respond to 
antibiotic treatment.40 Sequential cultures were taken over a period of 34 to 50 days 
after the initial infection. Streptococcus pneumoniae, Haemophilus influenzae and 
Moraxella catarrhalis were the predominant isolates in the initial cultures, but in 
subsequent cultures these bacteria were accompanied by anaerobes, such as 
Fusobacterium, Prevotella, Porphyromonas and Peptostreptococcus. The initial 
bacterial infection could have resulted in changes in the sinus microenvironment, 
such as impaired ventilation, mucous stasis and reduced oxygen level in the sinus, 
favouring the development of secondary anaerobic infection, which in turn was 
responsible for the prolonged disease. Streptococcus pneumoniae, Haemophilus 
influenzae and Moraxella catarrhalis have also been recovered from CRS patients, 
some of whom experienced acute sinus symptoms, but in a smaller proportion than 
in acute rhinosinusitis.149 It seems likely that these bacterial infections have a role 
in acute exacerbations of CRS, but it is not clear whether they participate in the 
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4.  Fungal rhinosinusitis  
4.1. Presence of fungi in the environment 
Fungi are ubiquitous in nature, comprising approximately 25% of the earth’s 
biomass.53 They have an important role in decomposing organic matter in natural 
recycling processes. It is estimated, that there are 1.5 million fungus species 
worldwide, of which 100 000 have been specifically identified.87 Only about 100 
are known to be primary pathogens in humans and animals, causing allergic 
reactions, infections and ingestion toxicity, and a few hundred more occur as 
opportunists.53,87 Most fungi reproduce by forming airborne spores. Fungal spore 
concentration in the air can easily exceed 100 000 spores/m3, and thus they 
constitute the largest portion of bioaerosols in the environment.53 The most 
common fungi in both indoor and outdoor settings belong to species Cladosporium, 
Alternaria, Penicillium and Aspergillus, indoor levels being usually 40-80% of 
outdoor levels.53 In addition, the common species include Basiospores and 
Ascospores outdoors and Aureobacidium indoors.53 
Fungal spore counts in the air show a marked geographic and seasonal variation. 
The highest counts are most often recorded in the summer and/or autumn 
months.2,75 In Finland, the Aerobiological Unit of the University of Turku routinely 
records the data of air spore counts of selected fungi throughout the year. Their 
statistics for Cladosporium and Alternaria show similar seasonal variation (see 
Figure 1 in the original publication II). The seasonal variation of fungi isolated 
from the nasal mucus has also been seen in the study of Buzina and colleagues, 
where they obtained mucus samples by flushing the noses of chronic rhinosinusitis 
patients and healthy controls.45 Cladosporium, Alternaria, Aureobacidium, which 
were the most prevalent fungal species among both groups, showed a significant 
seasonal fluctuation with a maximum in late summer/early autumn, suggesting 
merely a reflection of environmental exposure to fungi in the nasal cavity than a 
cause of the disease itself.  
4.2. Fungi in the pathogenesis of chronic rhinosinusitis 
In the recent years there has been an increasing interest in the possible fungal 
aetiology of CRS. Ponikau and colleagues detected fungi in nasal lavage (NAL) 
samples in 96% of 210 consecutive CRS patients and in 100% of 14 healthy 
volunteers, when novel mucus collecting and fungal culturing methods were 
used.246 An average of 2.7 (2.3 in controls) organisms per patients grew, with a 
maximum of eight (four in controls) different organisms per subject. 
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Cladosporium, Alternaria, Penicillium and Aspergillus were the most prevalent 
genera found in both groups. Of 101 surgically treated patients there were fungal 
elements present in histological samples in 81% and 93% met the criteria of 
allergic fungal rhinosinusitis (AFRS). The eosinophils in the mucin occurred 
independently from IgE-mediated hypersensitivity, and thus the authors proposed a 
term eosinophilic fungal rhinosinusitis instead of AFRS. In Europe Braun and 
colleagues reported similar results using similar specimen collection and culture 
methods as Ponikau and colleagues.32 There was no marked difference between the 
number and genera of organisms grown from the patient and the control samples 
either. The most common indoor fungal species, namely Cladosporium, Alternaria, 
Penicillium and Aspergillus, were the most prevalent fungal species also in this 
study. Their group conducted another study of 210 CRS patients and 23 healthy 
volunteers, using the same specimen collection technique as Ponikau, but 
identification was performed by polymerase chain reaction, with comparable 
results with the other two studies.45 Moreover, Catten and colleagues detected 
fungal DNA in 40% and 42% of nasal swabs taken from CRS patients and controls 
respectively.50 Based on these studies it is proposed nearly everyone has fungi in 
the nose and the mere presence of fungi in the nose and sinuses is not enough to 
explain their role in the pathogenesis of CRS. Furthermore, the fungal colonization 
of the nasal and paranasal cavities is present in 15% of newborn babies within the 
first days of life and increases to 94% in four months, suggesting the ubiquitous 
existence of fungi in essentially all humans.174 
The more recent results suggest a much broader role for fungi in CRS patients, such 
as non-infectious stimuli or targets for the eosinophilic inflammation. Eosinophils 
are generally regarded to play a role in host defence against larger, non-
phagocytosable organisms, such as parasites.106 Eosinophils also are able to destroy 
fungi by releasing proteins from granules they contain.181 In allergic/eosinophilic 
fungal rhinosinusitis the abundant tissue eosinophils are supposed to be on transit 
through the mucosa and migrate into the mucus, where they form clusters around 
fungal elements.33,246 IgE-mediated allergy to fungi in CRS has been supposed to 
be behind the eosinophilic inflammation.267 Even though a number of atopic CRS 
patients produce specific IgE against fungi, there is no evidence of this IgE 
production being the actual cause of the disease.64 The cytokines IL-5, IL-13 and 
VCAM-1 associated with eosinophil chemotaxis and survival are significantly 
elevated in sinus tissues from CRS patients independently of their allergy status 
when compared with healthy controls.123,124 The in vitro stimulation of peripheral 
blood mononuclear cells (PBMCs) with Alternaria extracts induced production of 
IL-5 and IL-13 in PBMCs from CRS patients, but not in those from healthy 
controls.277 A weaker response occurred after stimulation with Aspergillus and 
Cladosporium antigens, but not with Penicillium. In addition, PBMCs from CRS 
patients produced 5.5 times more IFN-γ when stimulated with Alternaria extract 
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than did PBMCs from healthy controls.277 INF-γ is known to enhance the parasite 
killing ability of eosinophils.226 These results suggest that CRS patients seem to 
respond to common airborne fungi by producing cytokines involved in the 
eosinophilic inflammation. 
4.3. Fungal rhinosinusitis 
Although the significance of fungi in the pathogenesis of CRS in general is in 
dispute, it is known that fungi are capable of invading the paranasal sinuses. It is 
estimated that approximately 5% to 10% of CRS patients have a diagnosis of 
fungal rhinosinusitis.110,190 Fungal rhinosinusitis presents in five distinct 
clinicopathological forms.82-84 The invasive forms are acute fulminant, chronic, and 
granulomatous (also called primary paranasal Aspergillus granuloma) invasive 
fungal rhinosinusitis. The non-invasive variants of fungal infection are sinus 
mycetoma (fungus ball) and AFRS, in which fungi are found within the sinus 
cavity without penetration of the mucosal barrier. The exact diagnosis of fungal 
rhinosinusitis is difficult to establish because they have many common signs and 
symptoms and only tissue examination, often with specific fungal stains, provides 
accurate diagnosis and classification.82,110 The role of fungal culture in the 
diagnosis of fungal rhinosinusitis is not determined. Culture is insensitive, as only 
20-40% of fungal infections are estimated to be culture positive, but it is often 
needed for fungal specification.110 Accurate classification of fungal rhinosinusitis is 
important, since the treatment and prognosis vary between the disease categories. 
4.3.1. Invasive fungal rhinosinusitis 
The diagnosis of invasive fungal rhinosinusitis requires findings of rhinosinusitis 
on radiological imaging and histopathologic evidence of fungal hyphae within 
sinus mucosa, submucosa, blood vessels, or bone. Classification of invasive fungal 
rhinosinusitis to three subcategories is based on the type and intensity of the 
infection estimated by clinical and histopathologic findings.83 Acute fulminant 
invasive fungal rhinosinusitis is characterized by rapid spread of the fungus into the 
adjacent tissues and intracranially often leading to death. Patients are usually 
immunocompromised having malignant disease, other cause of neutropenia, 
diabetes, or taking immunosuppressive drugs.267 They become acutely ill with 
fever, sinonasal infection, pale and ischemic mucosa, and headache/facial pain, 
which is in disproportion to physical findings. Anaesthesia of the nasal mucosa 
and/or facial skin is suggestive of an invasive prosess and does not occur in 
bacterial infections.  Necrotic septal ulcers (eschars) are traditionally described as a 
hallmark of invasive fungal rhinosinusitis but they are a late finding. Affected 
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tissues are necrotic, and histopathology show fungal invasion to mucosa and blood 
vessels, haemorrhage, vasculitis with thrombosis and extensive tissue necrosis with 
neutrophilic inflammation.83 The vascular fungal invasion is suggested to be 
responsible for the fulminant course. The saprophytic fungi of order Murorales, 
such as Rhizopus, Mucor, Rhizomucor and Absidia, and Aspergillus species are the 
most common fungi involved in acute fulminant form.83 The treatment includes 
wide surgical debridement, intravenous anti-fungal drugs and correction of the 
underlying condition. The prognosis depends upon early diagnosis and treatment, 
and it tends to be poor. 
The two other subgroups of invasive fungal rhinosinusitis have more chronic 
course of the disease, but they as well lead to death if left untreated.82,83 The 
chronic invasive fungal rhinosinusitis is clinically less aggressive than the acute 
fulminant form. It may present as proptosis or orbital apex syndrome, otherwise the 
clinical features are rather similar to the acute fulminant invasive fungal 
rhinosinusitis. The histopathologic studies show penetrating fungal hyphae, tissue 
necrosis with low-grade inflammation. Aspergillus fumigatus is the most common 
offending organism.83 As in the acute fulminant form, patients are usually 
immunocompromised. The most common underlying condition is diabetes. 
Treatment is the same as in acute fulminant fungal rhinosinusitis. However, the 
infection often recurs and the prognosis is poor. 
Granulomatous invasive fungal rhinosinusitis has mostly been reported in Sudan, 
but also in Pakistan, India and few sporadic cases in the United States.73,83,199 It is 
caused by Aspergillus flavus in immunocompetent patients. The clinical picture is 
chronic polypoid rhinosinusitis associated often with proptosis. Typically only one 
sinus is affected. Histopathology show profuse fungal growth with regional, 
superficial micro-invasion of fungal hyphae and noncaseating granuloma with giant 
cells. Eosinophilic inflammation, necrosis and vasculitis are sometimes noted.319 A 
concomitant negative mycobacterial stain must be present.83 Surgical resection 
followed by oral antimycotic drugs for months is needed.114 Relapse rate as high as 
80% and mortality is reported in patients treated by surgery alone. 
4.3.2. Non-invasive fungal rhinosinusitis 
The non-invasive forms of fungal rhinosinusitis are more common accounting for 
over 90% of cases.110 In sinus mycetoma (fungus ball) there is mucopurulent 
material within the sinus and histological examination reveals a dense 
conglomeration of fungal hyphae with a chronic inflammatory response in the 
adjacent mucosa without tissue necrosis or granulomas and no evidence of fungal 
Review of the Literature 37
invasion using special fungal stains.84 Usually only one sinus is affected. Patients 
present clinically with polypotic chronic rhinosinusitis. Patients are usually 
immunocompetent, but may have additional underlying risk factors including 
previous sinus surgery and trauma.267 The treatment of choice is surgery with the 
removal of all fungal material and also obstructing hypertrophic sinus mucosa. The 
prognosis is excellent and usually only one operation is needed.   
AFRS is the most controversial form of fungal rhinosinusitis. It was first described 
in 1983 and termed allergic Aspergillus sinusitis because of its histopathologic 
resemblance to allergic bronchopulmonary aspergillosis.153 Moreover, it was 
considered to be caused by a type I immediate hypersensitivity reaction to 
colonizing fungi leading to allergic inflammation of the sinus mucosa. Since then 
many other fungal species than Aspergillus, mostly dematiaceous fungi such as 
Bipolaris, Curvularia, Alternaria and Exserohilum, have been reported in 
association with allergic Aspergillus sinusitis like conditions and name was 
changed to AFRS.268 As also the IgE-mediated mechanism in its pathophysiology 
is in dispute, the term eosinophilic fungal rhinosinusitis is recommended by some 
investigators.246 In AFRS the characteristic feature is allergic mucin, which is a 
greyish-green material with the consistency of peanut butter containing eosinophils, 
Charcot-Leyden crystals and sparse non-invasive fungal hyphae. The consensus 
view of the criteria are lacking, but the latest American rhinosinusitis classification 
proposed following research criteria: CRS; oedema in the middle meatus or 
ethmoid area, or nasal polyposis; allergic mucin containing fungal hyphae and no 
histologic evidence of fungal invasion; CT findings of sinus mucosal disease; and 
evidence of fungal-specific IgE by means of skin testing or blood testing.196 The 
last criterion was excluded from the earlier classification by deShazo and Swain.86 
The treatment of AFRS is also a matter of controversy. Most reports are from the 
United States and no international consensus exits. Surgical resection of all mucin 
and polyps is required.267 Oral corticosteroids, most commonly prednisone 
following the modified allergic bronchopulmonary aspergillosis protocol 
postoperatively for up to one year, has been reported to provide clinical 
improvement and prolong time to subsequent sinus surgery without significant side 
effects.173,268 This is often followed by topical steroids.173 The role and efficacy of 
systemic antifungal drugs or antifungal irrigations is also unclear.99,173 An 
aggressive allergy management is recommended involving nasal steroid sprays, 
antihistamines and immunotherapy. In a retrospective analysis of 60 AFRS patients 
11.1% of patients receiving immunotherapy were re-operated compared to 33% of 
patients not receiving immunotherapy, suggesting the potential benefit of 
immunotherapy in preventing recurrence of AFRS.21 However, immunotherapy can 
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worsen patients' symptoms if therapy is started before surgery.190 Recurrence is 
common and close follow-up for years is recommended.173 
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5. Moisture exposure 
5.1. General aspects 
Home dampness, indicated by the presence of water damage, moisture or moulds, 
is common in Finland and it has been reported in up to 52% of randomly surveyed 
homes.167 In the dry Scandinavian climate moisture problems are not caused by 
general dampness, but rather occur as a consequence of leakage (water damage), 
capillary movement of soil water, or condensation in cases of insufficient 
ventilation or inadequate insulation. Adverse health effects associated with 
moisture exposure have been frequently reported during the last three decades. The 
possible mechanisms whereby damp building materials may promote diseases 
include allergic reactions to increased concentrations of mould or mites, toxic non-
allergic reactions to products of fungi or other microorganisms, and increased 
concentrations of other indoor air pollutants associated with moisture exposure.74 
The role of indoor fungi themselves is controversial, since there is no scientific 
evidence of adverse health effects in occupational settings with extremely high 
concentrations of fungal spores in the air.189,258 However, the growth conditions 
have a major impact on the inflammatory and cytotoxic potential of microbial 
spores, which could explain the poor correlation between healt effects and the 
fungal spore count.258,260 
An association between moisture and mould growth and increased frequency of 
respiratory, as well as non-respiratory symptoms among the people living or 
working in a damp building has been demonstrated in several studies.42,74,167,191,244 
Respiratory and mucosal irritation symptoms are the most common but a variety of 
non-specific symptoms has also been reported in association with moisture 
exposure, such as joint pain, nausea and vomiting, constipation, fainting spells, 
backache, headache, fatigue and bad nerves.191 Exposure to moisture or mould may 
increase the risk of recurrent respiratory infections including the common cold, 
bronchitis, rhinitis, or rhinosinusitis.161,167,241 In addition, a positive association has 
been reported between moisture exposure and allergic diseases and asthma.141,161 
Moreover, the risk of current asthma in moisture exposure homes was highest 
among subjects with atopic heredity. 
The health data has usually been collected by questionnaires, which rely entirely 
upon patients’ own recollection. This may be problematic in cases of rhinosinusitis 
because typical symptoms are at best only indicative and the pathological findings 
in the paranasal sinuses occur also in uncomplicated viral infections, thereby 
leading to over-interpretation.13,118 There are also reports of objective findings of 
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nasal mucosa irritation in association with moisture or mould exposure.137,218,255,329 
An elevation in pro-inflammatory cytokines IL-1, IL-6 and TNF-α in NAL fluid 
was seen in parallel with respiratory tract and eye irritation in subjects working in 
moisture-damaged buildings.137,255 A similar cytokine profile is also seen in viral 
rhinitis and acute rhinosinusitis, which are characterized by an acute inflammatory 
cell reaction and no major sequelae for the sinus mucosa.15 The duration of this up-
regulation may be longer when induced by environmental exposure, but only if the 
exposure continues, and may thus lead to more long-standing mucosal swelling and 
disturbances in sinus ventilation.255 The increased concentrations of ECP, a marker 
of the eosinophil activation, have been detected in NAL samples from people 
working in damp office building and from subjects exposed to formaldehyde, 
nitrogen dioxide, and Aspergillus species, possibly indicating a link between 
environmental exposure and chronic inflammation of the nasal mucosa.218,329 
5.2. Association with chronic rhinosinusitis and fungal rhinosinusitis 
There are few studies pointing to the possible effect of the environmental exposure 
to fungi on CRS and fungal rhinosinusitis. Dennis studied the effect of reduction of 
the environmental fungal load on the sinus mucosa in 639 patients with apparent 
CRS.81 The abnormal sinus mucosa findings persisted in patients who had recurrent 
exposure to airborne fungi, even after treatment consisting of saline nasal 
irrigations and antimicrobial nasal sprays containing two structurally different 
antibiotics, an antifungal and a steroid for 4-10 weeks. The author stated that CRS 
is likely caused by an immune response to fungal antigen and "As long as fungi 
remain, so will the irritation and the sinusitis". However, in the absence of a control 
group of subjects the results of this study should be interpreted with caution. In a 
Finnish study an association between self-reported rhinosinusitis and elevated 
serum IgG-levels for ten fungal species, for example, Aspergillus fumigatus, 
Aspergillus versicolor, Cladosporium cladosporioides and Stachybotrus atra, was 
reported in teachers exposed to indoor moulds, although there was not a statistical 
difference in the overall concentrations of 20 mould-specific IgG-antibodies 
between the study and control groups at the beginning of the study.234 After school-
building remediation the number of teachers reporting episodes of rhinosinusitis 
decreased from 37% to 11%, but there were no significant changes in IgG 
concentrations. 
Outbreaks of nosocomial invasive fungal infections, usually invasive aspergillosis 
in the lungs but also some cases in the sinuses, in immunocompromiced patients 
have been described in association with hospital construction or renovation, 
contaminated air filtration systems or contaminated construction materials, 
suggesting that the concentration of fungal spores in the air may play an important 
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role.316 In addition, nasopharyngeal colonization may be a risk factor for the 
acquisition of invasive aspergillosis.316 However, direct infections caused by indoor 
moulds are highly uncommon in immunocompetent individuals. In sawmill 
workers an intense exposure to fungal spores in the working environment did not 
induce an up-regulation of proinflammatory cytokines in NAL samples.258 Neither 
a correlation between mould count and AFRS was seen in a survey done in the 
United States, although there was a clear geographic distribution of AFRS with the 
highest incidence in hot and humid areas.100 In another study the predominant 
fungal species recovered from air samples from AFRS patients’ residences were 
also isolated from the mucin of its inhabitants.216 However, the authors were not 
able to establish an association between sick building syndrome and AFRS, and 
their results may reflect the influence of environmental exposure to the fungal 
findings in the nasal cavity rather than the disease pathogens themselves.   
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6. Matrix metalloproteinases 
6.1. Metalloproteinase structure and function 
Matrix metalloproteinases (MMPs) comprise a large family of at least 25 different 
endopeptidases that are collectively capable of degrading almost all components of 
the extracellular matrix and basement membrane.193,298 MMPs are part of a much 
larger metalloproteinase superfamily including also astacins, reprolysins (a 
disintegrin and metalloproteinases), and serralysins.28  
All MMPs have a similar domain structure. Every MMP has three conserved motifs 
assigning proteinases to MMP family, namely a signal peptide, a “pro” region 
containing the cysteine switch motif PRCGXPD to maintain latency, and a catalytic 
region that contains the zinc-binding active site.212,214,233 The active domain binds 
to three conserved histidines in the sequence HEXXHXXGXXHS.233 The 
conserved cysteine residue in the pro domain provides the fourth coordination site 
for the catalytic zinc2+ ion in the inactive state, and disruption of this bond is 
necessary for enzyme activation. MMPs have additional domains that are important 
in substrate specificity and recognition or interaction with other proteins or 
molecules including inhibitor binding.20,214,233 In the majority of MMPs, these 
domains are a proline-rich hinge-region and a hemopexin-like COOH terminal. 
Matrilysins (MMP-7 and MMP-26) lack the hemopexin domain, and in MMP-23 
they are substituted by a unique cysteine/proline-rich domain and an IL-1 type II 
receptor like domain.116,311 The two gelatinases, MMP-2 and MMP-9, have gelatin-
binding fibronectin type II like domains and the membrane-type MMPs contain 
additional transmembrane-domain anchoring them to the cell surface.166,330 Along 
with the domain structure, MMPs also share a similar gene arrangement, suggesting 
that they eventually have been generated by duplications of an ancestor gene.233 
The actions of MMPs in vivo are complex and diverse. Their main function is 
presumed to be extracellular matrix degradation in tissue remodelling, as MMPs 
can cleave extracellular matrix molecules. They have a key role in the embryonic 
development and tissue morphogenesis including angiogenesis, branching 
morphogenesis and wound healing.324 In addition to extracellular matrix 
remodelling, MMPs influence many cellular functions. They allow cell recruitment 
and transmigration by cleaving basement membrane components, activating 
cytoskeletal motor function, modulating cell-surface adhesive molecules and 
modifying chemoattractants.297,324 MMPs can alter extracellular micro-environment 
which results in cell proliferation or apoptosis.71,145 Furthermore, MMPs modify the 
activity of biologically active molecules, such as cytokines, defensins, serpins, cell 
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adhesion and surface molecules and receptors, by direct cleavage, release from 
bound stores, or modulating activity of their inhibitors.324 Via these non-destructive 
functions MMPs are further incorporated in developmental and anti-inflammatory 
defensive processes.111,195,228,324 However, MMP knock out mice do not show major 
development defects as expected by specific MMP functions in vitro.233,324 Thus, 
compensatory mechanisms must exist.  
Along with physiologic tissue remodelling and repair, MMPs are involved in 
various pathologic processes, such as inflammation, chronic degenerative diseases, 
periodontal diseases, cardiovascular diseases and tumour invasion and 
metastasis.201,212,214,233,286,323 However, due to the complex nature of MMP 
involvement and function, it cannot be concluded by their presence alone whether a 
specific MMP in a pathologic setting is contributing to a reparative or disease 
process. An example is MMP functions in malignant tumours. The MMPs are 
frequently overexpressed in various malignancies implicating in tumour growth, 
invasion and metastasis.136 Furthermore, they are associated with cell progression 
to the malignant phenotype, enhanced malignant potential and an adverse prognosis 
in cancer patients.5,25,136,299,340 In knockout mice lacking MMP-7 the tumorigenesis, 
angiogenesis and tumour progression are reduced.340 Controversially, MMP-8 has 
been demonstrated to exert anti-tumour activity in the chemical carcinogenesis 
model of skin tumours as well as in vitro in breast tumour cells .3,18 In addition, the 
integrin alpha-1 deficient mice have decreased vascularization of tumour xenografts 
due to increased level of circulating angiostatin generated by increased activity of 
MMP-7 and MMP-9 in these mice.251 Thus, increased expression of MMPs may 
both induce invasiveness of tumours and, paradoxically, lead to production of 
molecules that limit their growth. 
6.2. Regulation of metalloproteinases 
Under normal physiological conditions, the activities of MMPs are precisely 
regulated at the level of transcription, activation of the precursor zymogens, 
interaction with specific extracellular matrix components, and inhibition by 
endogenous inhibitors.212 The importance of each regulatory mechanism varies 
among different MMPs as well as by clearance and cell types.  
6.2.1. Transcriptional regulation 
The expression of most MMPs, with the exception of MMP-8 and MMP-9, is 
regulated transcriptionally.148 The polymorphonuclear (PMN) cell type MMP-8 and 
MMP-9 are synthesized in bone marrow, stored in the specific and the secretory 
Review of the Literature 44 
granules, respectively, in the neutrophils, and their activation is mainly regulated 
by selective subcellular granule release.338 As a general rule, the MMP genes are 
not expressed constitutively in vivo, and basal MMP levels in cell cultures are 
low.148 
A variety of extracellular stimuli may alter MMP gene expression, including 
cytokines, growth factors, hormones, oncogenic cellular transformations, chemical 
agents and ultraviolet B irradiation.136,212 In addition to soluble factors, cell-cell and 
cell-matrix interactions regulate the MMP gene expression.212 In general, IL-1, IL-
8, TNF-α, prostaglandin E2, TGF-α, parathyroid hormone and endotoxin up-
regulate MMP gene expression, whereas the enhanced expression is down-
regulated by suppressive factors including TGF-β, INF-γ, retinoic acids and 
glucocorticoids.148,185 Binding of these ligands to their receptors triggers a cascade 
of intracellular reactions mediated by mitogen-activated protein (MAP) kinases. 
Activation of MAP kinases culminates in the activation of transcriptional factors, 
activator protein-1 or polyoma virus enhancer A binding protein-3, in the promoter 
domain of MMP genes resulting in transcription of the corresponding MMP 
gene.136,256 
6.2.2. Activation of metalloproteinases 
With the exception of membrane-type MMPs, MMP-11, MMP-23 and MMP-28, 
which are activated intracellularly by furin, MMPs are secreted as inactive 
zymogens and are activated by the loss of the propeptide extracellularly or on cell 
membranes.236,237 This activation is mediated by proteinases or chemical agents 
through different pathways with the common features of the disruption of the 
cysteine residue and zinc ion interaction (cysteine switch), followed by the removal 
of the propeptide.315,323. 
The three-dimensional structure of MMP pro-domain consists of three α-helixes 
and connecting loops.323 The first loop between helix 1 and 2 is a protease-sensitive 
"bait region". In the substrate-binding cleft in the catalytic domain after helix 3 is 
an extended peptide region containing the conserved cysteine switch, which forms 
a fourth ligand of the active-site zinc, keeping the zymogen inactive. The 
proteolytic activation occurs in a stepwise manner in the bait region. First, the 
cleavage of exposed bait region partly activates the MMP and probably destabilizes 
the rest of the propeptide, including the cysteine switch–zinc interaction. This 
allows intermolecular processing by partially activated MMP intermediates or other 
active MMPs to occur, resulting in removal of the remaining propeptide and full 
activation of the MMP.211 Chemical activation relies also on this cysteine switch 
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model. The modification of the cysteine switch cause partial activation of the MMP 
and intramolecular cleavage of the propeptide.225 As in the proteolytic pathway, full 
activity is achieved by intermolecular processing.  
Several proteolytic enzymes, including plasmin, trypsin, tryptase, neutrophil 
elastase, cathepsin G, bacterial and fungal proteinases, can cleave off the pro-
peptide, resulting in diminished molecular weight and increased catalytic 
activity.61,165,203,261,288,289 In addition, recent studies indicate that in vivo, the 
proforms of certain MMPs may also be active while in full-size or in complex with 
certain proteins.19,97 Activated MMPs can further participate in processing other 
MMPs.206,212Also various chemical agents, such as organomercurials, gold(I)-
compounds, thiol-modifying agents, oxidized glutathione, urea, sodium dodecyl 
sulfate, chaotropic agents, and reactive oxygens are able to induce proMMP 
activation.261,290,291,323 Moreover, low pH and heat treatment can lead to activation.  
6.2.3. Inhibition of metalloproteinases 
The activity of MMPs can be inhibited by two endogenous inhibitors, including the 
circulating general inhibitor of MMPs α-2-macroglobulin and tissue-localized 
tissue inhibitors of metalloproteinases (TIMPs), or by various synthetic inhibitors.  
6.2.3.1.    Tissue inhibitors of metalloproteinases (TIMPs) 
TIMPs are the major endogenous MMP inhibitors in the tissues.323 They are 
capable of inhibiting the activities of all known MMPs, and thus have a central 
function in maintaining the balance between extracellular matrix deposition and 
degradation in different physiological processes.109 To date, there are four known 
members in TIMP-family: TIMP-1 to TIMP-4. Although TIMPs have similar 
inhibitory activities against most members of the MMP family, they differ in many 
aspects, such as interactions with proMMPs, solubility, regulation of expression, 
and tissue specific expression.134 TIMPs are able to control MMP activity in two 
levels. They inhibit activated enzymes by forming with them tight, noncovalent 1:1 
stoichiometric complexes resistant to heat denaturation and proteolytic 
degradation.134,289 TIMPs also regulate the activation process by controlling the 
autocatalytic activation of many proMMPs and forming complexes with 
proenzymes.78 
TIMPs also exhibit additional biological functions. TIMP-1 and TIMP-2 have 
erythroid-potentiating and cell growth–promoting activities along with anti-
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apoptotic functions.105,132,312 In contrast, TIMP-3 has pro-apoptotic activity.4 TIMP-
2, but not TIMP-1, inhibits endothelial cell growth.205 Moreover, overexpression of 
TIMP-1, TIMP-2, and TIMP-3 has been found to reduce tumour growth.323 These 
activities are distinct from MMP inhibition, and their mechanisms are largely 
unknown. All these functions of TIMPs can not be reached by using synthetic 
MMP inhibitors. 
6.2.3.2.    Synthetic inhibitors 
Synthetic inhibitors of MMP fall into three pharmacologic categories: 1) collagen 
peptidomimetics (batimastat and marimastat) and non-peptidomimetics (BAY 12-
9566, AG3340, CGS-27023A and BMS-275291), 2) tetracycline-derivatives, and 
3) bisphosphonates.136 Considering the chronic inflammatory respiratory tract 
diseases, the most interesting group is tetracycline-derivatives. These agents inhibit 
both the activity and production of MMPs including membrane-type 1 MMP via 
multiple mechanisms, including blocking the activity of mature MMPs, interfering 
with the proteolytic activation of pro-MMP into their active form, reducing the 
expression of MMPs, and protecting MMPs from proteolytic and oxidative 
degradation.108,136 Low-dose (20 mg twice daily for three months) doxycycline 
therapy in combination with non-surgical periodontal therapy reduced significantly 
but not completely gingival crevicular fluid and serum MMP-8 levels and improved 
clinical periodontal parameters over a 12-month period in patients with chronic 
periodontitis.95,286,287 The MMP inhibition along with the clinical improvement was 
detected as well in the murine model of toluene di-isocyanate induced asthma, 
where administration of doxycycline decreased airway inflammation and airway 
hyperresponsiveness together with down-regulation of MMP-9 expression.179 Also 
macrolide antibiotics, which may be as effective as prednisolone in chronic 
rhinosinusitis in long-term, low-dose administration, has been found to exert 
suppressive activity on MMP-2 and MMP-9 production from nasal polyp 
fibroblasts in vitro.151,331 Thus, macrolide antibiotics probably represent another 
group of antibiotics already in the clinical use demonstrating anti-MMP activity as 
a part of their therapeutic profile. 
6.3. Classification 
MMPs are classified into six main subfamilies, according to their substrate 
specificity, primary structures, and cellular localization: the matrilysins, 
collagenases, gelatinases, stromelysins, membrane-type MMPs and other MMPs. 
The last subfamily compromises of seven MMPs, which can not be classified in the 
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above categories. Here three different type MMPs studied in the CRS patients are 
discussed in detail. 
6.3.1. Matrilysin (MMP-7) 
MMP-7 together with MMP-26 belongs to the matrilysins subfamily of MMPs. 
They lack the C-terminal hemopexin domain as a common structural feature and 
are therefore considerably smaller than MMPs in general. MMP-7 is produced by 
blood monocytes, macrophages and epithelial cells in exocrine glands, intestine and 
airways, whereas expression of MMP-26 is found in placental macrophages and 
stromal cells.44,77,93,301 MMP-7 is constitutively expressed in non-injured, normal 
epithelium, implying its role in tissue homeostasis. MMP-7 can proteolytically 
activate α-defensins, an important component of mucosal innate immunity, in 
mouse small intestine and it may serve a similar function also in the mucosal 
epithelium of the respiratory tract.233,341 Moreover, significantly increased (25-50 
fold) expression and activation of MMP-7 were found after bacterial exposure in 
mucosal epithelial tissues, including airways.187 This up-regulation was specific for 
mucosal epithelial cells, and the expressions of other MMP examined (MMP-1, 
MMP-2, MMP-9, MT1-MMP/MMP-14) were not influenced. MMP-7 is also 
markedly up-regulated in migrating tracheal epithelial cells after injury, whereas 
MMP-7 knock-out mice showed no evidence of epithelial migration resulting in 
severe wound-repair defect.93 These results demonstrated that catalytic activity of 
MMP-7 is needed to facilitate cell migration and is essential for the repair of 
respiratory mucosal epithelium. 
6.3.2. Collagenase-2 (MMP-8) 
MMP-8 is a member of an interstitial collagenase subfamily of MMPs, including 
also collagenase-1 (MMP-1) and collagenase-3 (MMP-13). Collagenases have a 
unique capacity to degrade native fibrillar type I, II and III collagens, major 
structural components of the extracellular matrix. These interstitial collagens are 
composed of three polypeptide chains arranged in a rigid triple helix conformation, 
rendering them resistant to degradation by proteinases other than the interstitial 
collagenases. Collagenases can also degrade type VII, VIII, X collagens, gelatin 
and proteoglycans.130 Furthermore, they can inactivate serpins, including α1-
antitrypsin and α1-antichymotrypsin, and also MMP inhibitor α2-
macroglobulin.197,292,338 MMP-8 is the most effective collagenase to initiate type I 
collagen degradation and it is an initiator of collagen breakdown at the sites of 
inflammation, as well as in the atherosclerotic plaques and aortic aneurysms.135,342 
MMP-8 is also implicated in the pathogenesis of several chronic inflammatory 
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diseases characterized by excessive influx and activation of PMN cells, such as 
cystic fibrosis, rheumatoid arthritis, periodontal disease, and chronic skin 
wounds.192,220,250,286 MMP-8 seems to have an anti-tumour activity in breast 
carcinomas and skin tumours and anti-inflammatory properties in mouse model of 
asthma and allergen-induced airway inflammation.3,18,111,228 
MMP-8 was earlier regarded solely as a PMN specific MMP and designated as a 
neutrophil collagenase.130 However, the expression of the less glycosylated 
mesenchymal MMP-8 have been detected in various non-PMN cells, including 
synovial fibroblasts and endothelial cells, chondrocytes, gingival sulcular epithelial 
cells, odontoplasts and plasma cells.62,127,230,307,325 Mesenchymal MMP-8 is also 
expressed by benign and malign tumourgenic epithelial cell lines in vitro and by 
tumour cells in squamous cell carcinoma of the head and neck region in vivo.17,202 
In addition, inflamed human bronchial epithelial cells express MMP-8 mRNA and 
protein in vivo.253 The highly glycosylated PMN-type MMP-8 is stored in the 75-80 
kilodalton (kDa) latent form in the specific granules in the neutrophils and 
converted to a 65-70 kDa active form upon selective degranulation. After release 
from granules, a significant part of MMP-8 is associated to the membrane of 
neutrophils and exerts pericellular proteolysis.228 In non-PMN cells the inductive de 
novo synthesis of mesenchymal type MMP-8 is transcriptionally 
regulated.62,127,202,230 The 55-60 kDa latent mesenchymal type isoform is converted 
to 45-50 kDa active isoform upon activation by chymotrypsin, cathepsin G, trypsin-
2, MMP-3, MMP-7, MMP-10, and reactive oxygen metabolites.203,210 
6.3.3. Gelatinase B (MMP-9) 
Gelatinase A (MMP-2) and gelatinase B (MMP-9) comprise the gelatinases 
subfamily of MMPs. MMP-2 and MMP-9 have three gelatin-binding fibronectin 
type II –like domains that are important for their activity on type IV collagen, 
gelatin, and elastin.278 Type IV collagen, the principal substrate, is the main 
component of basement membranes and thus, MMP-2 and MMP-9 are usually 
expressed by endothelial cells, although other cells, such as stromal fibroblasts, 
macrophages and tumour cells, can also express them.9,275 Gelatinase expression 
also correlates with the invasive potential of various tumours.299 Gelatinases control 
the transepithelial migration of inflammatory cells (T cells, monocytes, eosinophils, 
and mast cells) by controlling the formation of transepithelial C-C-chemokine 
gradients in which chemokines are strongly expressed on the apical surface of 
epithelial cells relative to the interstitium.67 When inflammatory cells are recruited 
to the lungs, the recently extravasated cells traverse the pulmonary interstitium and 
the airway epithelium to enter the airway lumen, where they are cleared. Lack of 
MMP-2, affecting only eotaxin (CCL11), and MMP-9, affecting eotaxin, CCL7, 
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and CCL17, disrupts the normal cell trafficking into the airway lumen and 
favouring their accumulation in parenchyma. Thus, by generating several 
transepithelial chemokine gradients, MMP-9 is essentially implicated in the 
resolution of allergic inflammation. 
MMP-9 is secreted from degranulating neutrophils as a glycosylated 92 kDa latent 
form, and converted to a 82 kDa form upon activation via proteinase cascade by 
trypsin-2, neutrophil elastase, active MMP-2, MMP-3 and MMP-7.9,289,338 
Moreover, MMP-9 can be expressed and released in a 120 kDa complex form with 
29 kDa neutrophil gelatinase associated lipocalin (NGAL).162 MMP-9 is also 
produced by many cells that accumulate in allergic airway inflammation, such as 
eosinophils, mast cells, natural killer cells, dendritic cells and alveolar 
macrophages.9,48,193,223 In acute IgG immune complex induced lung injury the 
MMP-9-deficient mice had less severe lung injury when compared to wild-type 
controls, suggesting that MMP-9 is involved in the pathogenesis of the lung 
injury.334 In contrast, MMP-9 expression was up-regulated in vitro in the 
respiratory epithelial cells cultured from human nasal polyp tissue or human 
bronchial tissue during the wound repair.180 A marked MMP-9 activation occurred 
only in cells involved in the repair process located at the leading edge of a wound. 
Moreover, MMP-9 expression paralleled cell migration speed, implicating its role 
in the physiologic repair process in the respiratory epithelium. 
6.4. Metalloproteinase expression in chronic inflammatory airway diseases 
Tissue remodelling is a characteristic feature in many chronic lung diseases, such 
as loss of alveolar walls in emphysema, subepithelial fibrosis in asthma, intra-
alveolar fibrosis in idiopathic pulmonary fibrosis, and bronchiectasis in cystic 
fibrosis, involving extracellular matrix production and degradation.9,193 Since 
MMPs constitute the major proteolytic enzyme system responsible for the 
extracellular matrix remodelling, they have been investigated especially in lower 
respiratory tract diseases. Considering the fact that MMPs also have a central, non-
destructive, role in key biological activities in inflammation, innate immune 
response, and infection, MMPs are highly likely implicated in several ways in 
chronic inflammatory airway diseases too.306,324 Failures in these non-destructive 
processes, leading to sustained inflammation, have been emphasised of being 
caused by excessive extracellular protease activity.  However, an excess of TIMP 
over MMP has been proposed to favour airway remodelling in asthma.57,193 
Moreover, recent studies on MMP knock-out mice have shown that MMP 
deficiency can promote airway inflammation.111,195,228 
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MMP-9 has been found to be the predominant MMP in blood, sputum, 
bronchoalveolar lavage (BAL) fluid, and bronchial mucosa biopsy in asthmatic 
patients.9 TIMP-1, a major endogenous inhibitor of MMP-9, is also elevated in 
stable asthma to molar concentrations exceeding those of MMP-9.193 TIMP-1 is 
considered to have fibrogenic properties resulting from inhibition of MMP-9 and 
promotion of growth of fibroblasts and myofibroblasts.131 The TIMP-1/MMP-9 
imbalance could lead to pathologic collagen deposition leading to thickened 
airways with restricted airflow. High TIMP-1/MMP-1 molar ratio correlates with 
the disease severity and predicts also poor response to oral corticosteroids in 
asthmatics, supporting the fibrogenic theory.29,193,321 In contrast, an increase in 
MMP-9, resulting in a low TIMP-1:MMP-9 ratio, has been demonstrated in 
decompensated asthma, under acute asthma exacerbations or after allergen 
challenge, suggesting that MMPs may be involved in the different tissue 
degradation processes and/or cellular functions in different states of the disease.182 
Significant increases of MMP-1, MMP-2 and MMP-8 have also been reported in 
the sputum or BAL fluid from asthmatics.49,252,303 MMP-8 is of special interest in 
the lung remodelling, as it hydrolyzes most efficiently type I collagen, which is also 
the major interstitial collagen type in human lung extracellular matrix.130 The 
secreted MMP-8 in BAL fluid has been detected to convert into active form in 
steroid naïve or uncontrolled severe asthma, but not in clinically stable disease, nor 
in healthy controls.252 In severe disease both PMN-type and mesenchymal-type 
MMP-8 isoforms were observed to be converted to active forms. Moreover, a focal 
and strong MMP-8 immunoreactivity was found in bronchial epithelial cells 
especially in the injured areas, indicating perhaps more advanced destructive and 
irreversible tissue injury rather than inflammation itself. High amounts of 
functionally active collagenases, mainly MMP-8, have been shown in BAL fluid 
from patients with bronchiectasis, a disease characterized by irreversible tissue 
injury.253,271 Like in asthma, the MMP-8 expression correlated with the disease 
severity.252,253,271 However, the functions and mechanisms of action of MMP-8 are 
not well established in inflammatory disorders.  
Recently, MMPs have been shown to exhibit unexpected anti-inflammatory 
properties in respiratory diseases. Owen and colleagues found in 
lipopolysaccharide (LPS)-induced lung inflammation greater accumulation of PMN 
cells and increased myeloperoxidase activity in the alveolar space in MMP-8 
knock-out mice when compared to wild type mice, representing defensive role of 
MMP-8.228 This anti-inflammatory function of MMP-8 was demonstrated and 
extended also in allergen-induced airway inflammation, in which MMP-8 knock-
out mice were found to have enhanced neutrophilic inflammation in BAL fluid and 
eosinophilic infiltration in airway walls together with increased levels of IgE and 
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IgG1 in serum and of IL-4 in BAL fluid.111 In addition, MMP-9 knock-out mice 
have been found to have significantly heightened airway inflammation after 
allergen challenge including increased number of eosinophils in BAL fluid and 
lung tissue accompanied by enhanced levels of IL-4, IL-5 and IL-13 and pro-
eosinophilic chemokine eotaxin in comparison with wild type mice.195 Moreover, 
inflammation persisted longer in MMP-9 knock-out mice. Similar inflammatory 
features, namely enhanced levels of Th2 cytokines and eosinophils, were found 
both MMP-8 and MMP-9 knock-out mice, suggesting a synergic function of MMP-
8 and MMP-9 in the control of airway allergic inflammation.  
6.5. Metalloproteinase expression in chronic rhinosinusitis 
There is only limited data concerning MMPs in CRS. However, CRS, especially 
the polypoid form, and asthma share several similar inflammatory features, 
suggesting a common pathophysiology.30,245,283 The elevated levels of MMP-9 and 
TIMP-1 were found in CRS, whereas in nasal polyposis MMP-7 and MMP-9, but 
not TIMP-1, were up-regulated.177,336 Immunohistochemical staining revealed the 
accumulation of MMP-7 and MMP-9 in the subepithelial region and around blood 
vessels in the nasal polyps.336 In particular in the nasal polyposis the inflammatory 
cells stained positive for MMP-7 and MMP-9, but not for TIMP-1, were found 
inside the pseudocysts, pointing to their degradative function in nasal polyposis 
pathogenesis. In addition, increased MMP-9 inside the extracellular matrix after 
sinus surgery was found to predict poor healing quality, although it did not 
correlate with edema, fibrosis, or overall inflammatory reaction.337 The 
investigators did not study MMP-9/TIMP-1 molar ratio, which has been evaluated 
in predicting corticosteroid efficacy in asthma. Lechapt-Zalcman and colleagues 
studied MMP-2 also in nasal polyposis patients, but the level of both latent and 
activated forms did not differ from those observed in control samples.177 
There are three studies done by Suzaki and his workgroup in Japan examining anti-
MMP-effect of pharmaceutical agents in nasal polyposis or rhinitis in vitro.8,151,213 
Every study evaluated the influence of the drug in question on the MMP-2 and 
MMP-9 levels and MMP-2 and MMP-9 mRNA expression in cell cultures after 
stimulation of MMP expression by TNF-α. Both fluticasone propionate and 
roxitromycin caused significant suppression of MMP levels and MMP mRNA 
expression in nasal polyp fibroblasts.151,213 In the third study fexofenadine 
hydrochloride inhibited as well the MMP levels and MMP mRNA expression in 
nasal polyp fibroblasts taken from patients with allergic rhinitis and in nasal 
mucosal cells from septal deformity patients without allergy.8 The investigators 
concluded that inhibitory action on MMP activity and tissue remodelling may 
underlie the clinical efficacy of these drugs in nasal polyposis and allergic diseases. 
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The interpretation must be done with caution, as the MMP functions in the upper 
respiratory tract diseases are largely unknown. Moreover, in the perennial allergic 
rhinitis patients TIMP-1 and TIMP-2 mRNA were present in large amounts in the 
nasal mucosal samples, whereas only minimal quantity of MMP-1, MMP-2, MMP-
3 and MMP-9 mRNA were found in the same samples.274 There was no significant 
difference in the MMP and TIMP levels between patients and healthy controls, 
raising the question about the significance of MMPs in the allergic rhinitis. 
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AIMS OF THE STUDY 
I. To study the full clinical picture, including patient history, microbiology and 
histology, of chronic rhinosinusitis with nasal polyposis in patients operated 
on for this condition in order to find out possible causative factors for the 
chronicity of the disease. 
II. To investigate the impact of moisture exposure on chronic rhinosinusitis with 
nasal polyposis and to evaluate the seasonal variation of fungal and bacterial 
findings in the healthy nose. 
III. To evaluate possible up-regulation and activation of MMP-8 in chronic 
rhinosinusitis with nasal polyposis, and to study the relationship between 
MMP-8 and pro-inflammatory cytokines IL-8 and TNF-α. 
IV. To study up-regulation and activation of metalloproteinases MMP-7, MMP-8 
and MMP-9 in relation to TIMP-1 in chronic rhinosinusitis with nasal 
polyposis. The MMP function, protective or destructive, is further evaluated 
by comparing patients with more active disease, estimated by tissue 
eosinophilia and a need for re-operations during three-year period. 
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MATERIALS AND METHODS 
1. Study population 
Study population consisted of 30 patients undergoing a paranasal sinus operation 
due to chronic rhinosinusitis with nasal polyposis (Table 1). All patients had a 
history of chronic rhinosinusitis lasting longer than twelve weeks in spite of 
appropriate conservative treatment. They also had findings of mucosal swelling and 
retention in some of the paranasal sinuses in preoperative CT-scan. The presence of 
polyps was assessed by anterior rhinoscopy and further confirmed during the 
endoscopic operation. 
Study I. All 30 patients were enrolled to Study I. Twelve patients were men (mean 
age 47.3 y, range 36-68 y) and 18 patients were women (mean age 48.4 y, range 
28-66 y). Nineteen patients (63%) had earlier had one or more sinus operation 
including polypectomy, antrostomy, endoscopic sinus surgery (ESS) or a Caldwell-
Luc-operation. Moreover, two patients had had a (rhino)septoplasty. Fifteen 
patients (50%) reported allergic rhinitis, 17 patients (57%) had asthma and five of 
them (29%) had ASA intolerence. These five patients were all operated on at least 
once previously. Altogether four patients (13%) were immunocompromised: three 
subjects had specific IgG subclass deficiency and one had IgG III and IgM 
deficiencies. All four patients had had several operations.  
Study II. Twenty-eight patients (11 males, mean age 45.9 y, range 36-68 y; 17 
females, mean age 47.9 y, range 28-68 y) were enrolled to the second study. 
Nineteen of them (68%) had earlier had one or more nasal or sinus operation. 
Fifteen patients (54%) had self-reported allergic rhinitis, 17 patients (61%) had 
asthma and five of them (29%) had ASA intolerance.  
Study III. Thirteen patients (five males, mean age 44.6 y, range 36-53 y; eight 
females, mean age 47.4 y, range 28-68 y) were recruited to the third study. Nine 
patients (69%) had been operated on earlier, eight patients (62%) had self-reported 
allergic rhinitis, eight patients (62%) had asthma and two of them (25%) had also 
ASA intolerance. All patients used topical corticosteroids.  
Study IV. Twenty-four patients (11 males, mean age 45.9 y, range 36-68 y; 13 
females, mean age 46.5 y, range 28-68 y) were enrolled. Thirteen patients (54%) 
had allergic rhinitis, 14 patients (58%) had asthma, and three asthmatic patients 
(21%) were ASA intolerant. All except one patient had used topical corticosteroids,  
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Table 1. The history of moisture problems, patient history, previous nose or sinus 
operations, results for tissue eosinophilia and fungal examinations, and clinical diagnosis 
in 30  patients operated for chronic rhinosinusitis with nasal polyposis (CRSwNP) 
Male       36  - A, AR, ID  +  + Yeast cells  -  - AFRS-like sdr
Female   49  - AR  +  - Fungal hyphae  +  - Mycetoma
Male       36  H  -  +  +  -  +  - AFRS-like sdr
Female   53  H A, AR  +  +  -  -  - CRSwNP
Female   47  - A, AR  -  +  -  -  - CRSwNP
Female   29  -  -  -  -  - -  - CRSwNP
Female   53  H A, ASA  +  +  - -  - CRSwNP
Male       44  -  -  -  +  - -  - CRSwNP
Male       68  - A  -  +  - -  - CRSwNP
Female   53  - A  +  +  - -  - CRSwNP
Male       58  W  -  -  - Fungal hyphae  +  - Mycetoma
Female   44  - AR  +  +  -  -  - CRSwNP
Male       40  H A, AR, ID  +  +  -  -  - CRSwNP
Female   44  W AR  - Not taken  - Not taken  - CRSwNP
Female   56  - ID  +  -  -  -  - CRSwNP
Female   38  - AR  -  -  -  -  - CRSwNP
Female   28  - A, AR  -  -  -  -  - CRSwNP
Female   52  W A, AR  +  -  -  -  - CRSwNP
Female   66  - A, ASA, AR  +  -  -  -  - CRSwNP
Female   56  H A, ASA  +  +  -  +  - AFRS-like sdr
Female   42  - A, AR  +  -  -  -  - CRSwNP
Male      36  - A, ID  +  +  -  -  - CRSwNP
Female   54  W A, AR  +  +  -  -  - CRSwNP
Male       48  W+H A, AR  +  +  -  -  - CRSwNP
Male       53  - AR  +  + Fungal hyphae  + Aspergillus niger AFRS-like sdr
Male       45  W A  +  +  -  -  - CRSwNP
Male       41  W  -  -  -  -  -  - CRSwNP
Female   51  W A, ASA  +  +  -  -  - CRSwNP
Male       62  NA  -  -  +  -  -  - CRSwNP
Female   56  NA  -  +  + Fungal hyphae  - Aspergillus fumigatus Mycetoma
H, Moisture problem at home; W, Moisture problem at work; NA, Not ascertained; A, Asthma; AR, Allergic rhinitis; ASA, Aspirin intolerance; ID, 
Immunodeficiency; AFRS-like sdr, Allergic fungal rhinosinusitis like syndrome
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two patients had short course of oral prednisone preoperatively, and two patients 
had low-dose, long-term oral prednisone. During the three-year period following 
the initial operation nine patients (38%) were re-operated, of whom eight patients 
had tissue eosinophilia.  
Twenty healthy volunteers (nine males, mean age 37.4 y, range 30-46 y; 11 
females, mean age 39.9 y, range 29-60 y) from the Department of 
Otorhinolaryngology without any history of recurrent or chronic rhinosinusitis or 
nasal or sinus operations served as volunteer controls. 
2. Patient interview 
At the time of the operation the patients were interviewed about their medical 
history, which included questions on allergic manifestations, some background 
factors and environmental factors. The questions were derived from the 
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Miljömedicin 040 questionnaire. The questions on allergy were as follows: “Have 
you now or have you ever had asthma; hay fever or other allergic rhinitis?” The 
asthmatic patients were queried about ASA intolerance. Moreover, the subjects’ 
former nasal or sinus operations were noted. Moisture problems at home or at work 
were assessed by positive answers to at least one of the following questions: (1) 
“Has there been an odour of mould at your home or workplace in the last three 
years?” (2) “Have you had visible mould growth or damp stains at your home or 
workplace in the last three years?” (3) “Has there been repair due to the moisture 
damage at your home or workplace in the last three years?”  
3. Specimen collection 
Patients’ microbiological (Study I and II) and metalloproteinase (Study III and IV) 
specimens were collected during the endoscopic operation. Mucus from the 
paranasal sinus was placed into an empty sample tube for fungal studies and in 
modified Stuart transport medium (Transpocult; Orion Diagnostica, Espoo, 
Finland) for bacterial culture. A specimen for fungal staining was taken with a 
sterile cotton swab and placed directly onto a microscope slide. The slide was then 
air-dried. Mucus from the affected paranasal sinus was placed into a sample tube 
containing 1 mL phosphate buffered saline (PBS) and frozen directly at -20○C for 
metalloproteinase analysis. The biopsy for histological analysis was obtained from 
the same paranasal sinus as the mucus. 
NAL method, described earlier by Hirvonen and colleagues, was used with some 
modifications for collecting samples from the control subjects and also for cytokine 
analysis from 15 patients.137 In patients NAL was done preoperatively to prevent a 
possible impact of operation on cytokine levels. In brief, each nostril was flushed 
through with 5 mL of PBS using a 5 mL sterile syringe and a sterile butterfly 
cannula of about 3 cm in length. The cut end of the cannula was placed inside the 
nostril posterior to the nasal vestibulum. The patient closed the nostrils by pinching 
them firmly together and leaned forward. PBS was pushed back and forth twice and 
finally collected into the syringe. Any residual PBS remaining in the nostril was 
collected in a pan placed underneath the nose and collected into the syringe. 
About 2 mL of NAL fluid was placed into an empty sample tube for fungal 
examinations. Bacterial culture was collected by dipping a sterile cotton swab 
soaked in activated charcoal in the fluid. It was placed into a Transpocult tube. 1 
mL of NAL fluid was separated for MMP and TIMP-1 analysis and frozen at -
20○C. The NAL sample was further processed for cytokine analysis. The sample 
was centrifuged, the cells were re-suspended in about 2 mL of supernatant and the 
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suspension was incubated for 24 h at 37○C. The suspension was centrifuged and the 
supernatant was collected and frozen at -70○C for later cytokine analysis.  
To study the seasonal variation in controls the NAL was done twice from the same 
subjects: first in January and again in September.   
4. Specimen handling 
4.1. Bacterial culture 
The standard methods used in the diagnostic laboratories of Helsinki University 
Central Hospital to culture and identify both bacteria and fungi were used. The 
bacterial samples were inoculated onto the following media: chocolate agar for the 
isolation of aerobes; blood agar with colistin to select for Streptococcus sp; 
fastidious anaerobic agar for all anaerobes; blood agar with neomycin and 
vancomycin for Bacteroides sp; and thioglycollate broth for enrichment culture. 
Aerobic cultures were incubated at 36○C in an atmosphere containing 5% CO2. The 
plates were examined after 24 h and 48 h. The anaerobic cultures were incubated in 
an atmosphere of 4-10% CO2 (the GasPak, Becton Dickinson Microbiology 
Systems, Cockeysville, Md) and examined after 48 h. Both aerobic and anaerobic 
plates were cultured five more days and examined at day seven in case of negative 
growth after 48 h. 
4.2. Fungal staining and culture 
The fungal specimen was first vortexed to mechanically disperse the mucus. 
Calcofluor white fluorescence staining was carried out using the processed sample 
or the sample placed directly onto a microscope slide and the preparation was 
examined using a fluorescence microscope with 40-fold magnification. The 
remaining sample was plated out on Sabouraud dextrose agar containing penicillin 
6 mg/L and streptomycin 26mg/L. The cultures were incubated at 28oC and 37oC 
and examined at day seven and day ten. 
4.3. Eosinophil staining and histology 
For eosinophil staining the lavage sample was centrifuged 1500 revolutions per 
minute for 10 minutes. Cells were fixed on a microscopy slide air-drying. The 
slides were stained first in eosin-solution (Merck), rinsed quickly in water followed 
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by rinsing with ethanol and stained again in methylthionin-solution (Merck). The 
slides were finally rinsed with water and ethanol and air-dried. The sample was 
considered as positive, if any eosinophils were detected under the microscope.  
All histological samples were stained with hematoxylin and eosin and with Periodic 
acid-Schiff staining. If the Periodic acid-Schiff staining was negative for fungi the 
Gomori methenamine silver staining method was done. 
4.4. Immunofluorometric assay for MMP-8 
MMP-8 levels were analyzed by a time-resolved immunofluorescence assay as 
described by Hanemaaijer and colleagues.127 The monoclonal MMP-8 specific 
antibodies 8708 and 8706 (Medix Biochemica Oy Ab, Kauniainen, Finland) were 
used as a catching and tracer antibody, respectively. Europium-chelate was used to 
label the tracer antibody. The samples were diluted in assay buffer containing 20 
mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 50 µM ZnCl2, 0.5% bovine 
serum albumin, 0.05% sodium azide and 20 mg/L diethylene-triamine-penta-acetic 
acid and incubated for one hour, followed by incubation for one hour with the 
tracer antibody. Enhancement solution was added, and after five minutes, the 
fluorescence was measured using 1234 Delfia Research Fluoremeter (Wallac, 
Turku, Finland). The levels of MMP-8 were expressed as ng/mL and converted to 
pmol/mL for the study IV. 
4.5. Enzyme-linked immunosorbent assays for MMP-7, MMP-9 and  
TIMP-1 
MMP-7, MMP-9 and TIMP-1 concentrations were determined using commercially 
available enzyme-linked immunosorbent assay (ELISA) kits. Biotrak ELISA 
systems (Amersham Biosciences UK Ltd, Buckinghamshire, UK) were used for 
MMP-7 and -9 according to the manufacturer’s protocol and DuoSet ELISA 
development Systems (R&D Systems, Minneapolis, USA) for TIMP-1, 
correspondingly. All samples were analysed in duplicate. The so called secondary 
antibody in each kit was conjugated with horseradish peroxidase and tetra methyl 
benzidine was used as a substrate. The absorbance was measured at 450 nm using 
Labsystems Multiskan RC (Thermo Bioanalysis Corporation, Santa FE, USA). The 
levels of MMPs and TIMP-1 were expressed as ng/mL and converted to pmol/mL. 
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4.6. Western immunoblotting for MMP-8, MMP-9 and TIMP-1 
The molecular weight forms of MMP-8, MMP-9 and TIMP-1were analysed by 
Western immunoblotting analysis using specific rabbit polyclonal anti-human 
MMP-8, MMP-9 and TIMP-1 antibodies as described by Prikk and colleagues.252 
After sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
run under non-reducing conditions, the proteins in the gel were electrophoretically 
transferred onto a nitrocellulose membrane (Bio-Rad Laboratories, Richmont, 
California). After the unoccupied sites were blocked with 3% gelatin, the 
membrane first reacted with the primary antibody (1:500) and then with the 
alkaline phosphatase conjugated secondary antibody. The molecular weight forms 
of MMP-8 were visualized to photographic film using enhancement 
chemiluminescence systems (Amersham Biosciences). Quantization was carried 
out with a Bio-Rad Model GS-700 Imaging Densitometer using analysis program 
of Bio-Rad 253. Data is expressed as densitometric arbitrary units. Recombinant 
human proMMP-9 and TIMP-1 were used as positive controls for MMP-9 and 
TIMP-1. Human neutrophil and rheumatoid synovial culture media were used as 
positive controls for PMN-type and mesenchymal type MMP-8 isoforms, 
respectively. 
4.7. Gelatin zymography for MMP-9 
Gelatinolytic activity was analysed by zymography using 1mg/mL gelatine as 
substrate. After SDS-PAGE electrophoresis the gels were washed in 50mM Tris-
HCl, 2.5% Tween 80 and 0.02% (w/v) NaN3 for 30 min; followed by the same 
buffer supplemented with 1 µM ZnCl2 and 5 mM CaCl2 for 30 min; and finally 
incubated in 50 mM Tris-HCl, 5 mM CaCl2, 1 µM ZnCl2, and 0.02% (w/v) NaN3 at 
37°C for 24 h. The reaction was interrupted by staining the gels with 0.1% 
Coomassie Brilliant Blue R250 and then destained in 10% acetic acid, methanol 
solution. The gelatinolytic activity was visualized as clear bands against a blue 
background and the band intensity was quantified with a Bio-Rad Model GS-700 
Imaging Densitometer using analysis program of Bio-Rad. Pre-stained low range 
molecular weight SDS-PAGE standards were used as molecular weight markers.289     
4.8. Analysis of cytokines 
The concentrations of IL-8 and TNF-α in the supernatant of NAL fluid were 
measured using the Quantikine human ELISA kit (R&D Systems, Minneapolis, 
USA) according to the manufacture's protocol. Cytokine levels were expressed as 
pg/mL. 
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5. Statistical analysis 
The studies I and II were mainly descriptive and no statistical analysis was done.  
In the studies III and IV data are expressed as median and 25-75 interquartile range 
(IQR). The MMPs and TIMP-1 levels in the CRS groups and in the control subjects 
were compared using the Mann-Whitney U test. The exact probability test was used 
to compare the need for re-operation between eosinophilic and non-eosinophilic 
CRSwNP patients (study IV). Correlations were described with correlation 
coefficient r and their respective P-value. P-values under 0.05 were considered 
significant. 
6. Ethics 
The study was approved by the Ethical Committee of Helsinki University Central 





1. Microbiology of chronic rhinosinusitis with nasal polyposis           
(I, II, IV) 
1.1. Bacterial findings (I, II) 
Table 2 lists the bacteria found in patients and in controls. Twenty-eight out of 30 
patients (93%) had positive bacterial culture. In ten cultures (33%) two or more 
bacteria were cultured. At least one species of aerobic bacteria was cultured from 
27 patients (90%) and anaerobic bacteria from three patients (10%). The most 
common aerobic bacteria was Staphylococcus aureus, which was isolated from ten 
patients (33%); followed by coagulase negative Staphylococci (23%). The only 
anaerobic species found was Propionibacterium acnes. In the control group 14 
cultures (70%) were positive in January and in September bacteria were isolated 
from all samples. The two most common bacterial species in both control group 
samples were coagulase negative Staphylococci (40% in January vs. 68% in 
September) and Staphylococcus aureus (21% vs. 11%, respectively). The only 
anaerobic bacterium found in the control samples was Propionibacterium acnes in 
one subject in September. 
Table 2. Bacteria isolated in sinus mucus samples from the chronic rhinosinusitis with 
nasal polyposis patients and from nasal lavage samples collected in the winter and in the 
autumn from healthy controls 
Patients n (%) Controls n (%)
n=30 Winter n=20 Autumn n=19
Staphylococcus aureus 10    (33%) 5     (25%) 2     (11%)
Coagulase negative Staphylococci* 7      (23%) 8     (40%) 13   (68%)
Propionibacterium acnes 3      (10%)  - 1     (5%)
Streptococcus viridans 2       (7%) 1      (5%)  - 
Stenotrophomonas maltophilia 2       (7%)  -  - 
Escherichia coli 2       (7%) 1      (5%) 2**  (11%)
Klebsiella pneumoniae 2       (7%) 1      (5%)  -
Klebsiella oxytoca 2       (7%) 1      (5%)  -
Haemophilus influenzae 2       (7%)  -  -
Proteus mirabilis 2       (7%)  -  -
Streptococcus pneumoniae 1       (3%)  - 1      (5%)
Corynebacterium sp. 1       (3%)  - 1      (5%)
Neisseria meningitidis  -  - 1      (5%)
Enterobacter sp   - 1      (5%)
Culture positive 28    (93%) 14    (70%) 19    (100%)
Two or more bacteria 10    (30%) 2      (10%) 6      (32%)
* includes Staphylococcus epidermidis







1.2. Fungal findings (I, II) 
Seven out of 30 patients (23%) had one or more findings suggesting fungal 
infection (Table 1). Three patients had clinical and histological findings consistent 
with sinus mycetoma. The other four patients were considered as having AFRS-like 
syndrome. No invasive fungal infections were discovered. Fungal staining of the 
mucus was positive in five patients: one patient had yeast cells and four patients 
had fungal hyphae. The cultures were positive in only two patients: one Aspergillus 
fumigatus and one Aspergillus niger. Both patients had also fungal hyphae present 
in the sinus mucus sample. There were five specimens positive for fungal hyphae in 
histological samples stained with Periodic acid-Schiff. Only in two of these five 
specimens were fungal hyphae visible in samples stained with hematoxylin-eosin 
staining. Gomori staining yielded no additional positive findings.  
In the control group all NAL samples were negative for fungi in January, but in 
September fungi were isolated from NAL samples of three subjects. Both 
Cladosporium and Alternaria were cultured from two subjects and Cladosporium 
from one. No seasonal effect on fungal findings was seen in the patient group. 
1.3. Eosinophils (I, IV) 
Tissue eosinophilia was present in 19 histological specimens (63%) (Table 1). 
Secretion eosinophilia was also examined from 24 patients. Of these 24 samples, 
eight were positive for eosinophils and four of them had also tissue eosinophilia. 
All of these eight patients had asthma or allergic rhinitis. Of seven patients with 
some finding of fungi none had secretion eosinophilia, but five had tissue 
eosinophilia. In the control group all samples were negative for eosinophils. 
Sixteen out of 24 patients (67%) entering the Study IV had eosinophilic 
inflammation determined by eosinophils present in tissue biopsy obtained from the 
same paranasal sinus as the mucus and stained with hematoxylin and eosin. 
2. Chronic rhinosinusitis with nasal polyposis and moisture exposure 
(II)  
Thirteen of 28 patients (46%) reported a certain degree of moisture damage at work 
or at home within the last three years (Table 1). Seven patients (54%) reported 
moisture problems at work, five patients (38%) at home and one patient (8%) both 
at work and at home. Two patients reported an odour suggestive of mould at work 
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and occupational symptoms also in fellow workers. The remaining 11 patients had 
visible mould, water damage or repair done due to the moisture damage at home or 
at work. The level of indoor exposure in the control subjects was not ascertained. 
When the 13 patients who had reported moisture damage were compared with 
those 15 patients who did not, the occurrence of one or more positive fungal 
findings was 23% vs. 20%, positive bacterial culture 92% vs. 93%, two or more 
bacterial species in the culture 23% vs. 33%, and tissue eosinophilia 75% vs. 53% 
respectively. Seventy-seven % vs. 60% of the patients previously had undergone 
one or more nasal or sinus operations. The variants of fungal rhinosinusitis 
distributed evenly: one mycetoma patient and two with an AFRS-like syndrome in 
both groups. The bacterial species isolated from patients with or without a history 
of moisture problem did not differ from species isolated from healthy controls. 
3. MMPs, TIMP-1 and cytokines in chronic rhinosinusitis with nasal 
polyposis (III, IV) 
3.1. Results for MMP, TIMP-1 and cytokine analysis (III, IV) 
Study III. The concentration of MMP-8 in CRSwNP patients’ samples (median 
83.0 ng/mL, IQR 24.8-570.2 ng/mL) was significantly elevated in relation to the 
control samples (median 3.6 ng/mL, IQR 1.1-21.3 ng/mL) (P<0.01). In addition, 
the concentration of IL-8 was significantly increased in patients (median 419.9 
pg/mL, IQR 60.0-689.8 pg/mL) when compared to controls (median 25.2 pg/mL, 
IQR 9.2-61.7 pg/mL) (P<0·01). There was also a statistically significant difference 
in the median concentration of TNF-α in CRSwNP patients (median 0.8 pg/mL, 
IQR 0.6-1.8 pg/mL) in relation to controls (median 0.1 pg/mL, IQR 0-0.3 pg/mL) 
(P<0·01), but the concentrations were overall very low.  
When eight patients with asthma were compared with five non-asthmatic patients, 
the median concentrations of MMP-8 were 31.1 ng/mL and 188.6 ng/mL, IL-8 
were 583.9 pg/mL and 79.7 pg/mL, and TNF-α 0.8 pg/mL and 0.6 pg/mL, 
respectively. The differences were not statistically significant. 
Study IV. The concentrations of MMPs and TIMP-1 together with their molar 
ratios are shown in Table 3 and 4. The eight patients without tissue eosinophilia 
had significantly increased levels of MMP-8 and MMP-9, together with the 
enhanced MMP-8/TIMP-1 and MMP-9/TMP-1 molar ratio, when compared to 16  
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Table 3. The median and 25-75 interquartile range of MMP and TIMP-1 concentrations 
(pmol/mL)  in controls; in CRSwNP patients with tissue eosinophilia (Eos+) and without it 
(Eos-); and in same patients re-operated on during 3-year-period after initial operation 
(Re-op+) and not re-operated on (Re-op-)   
MMP-7 MMP-8 MMP-9 TIMP-1 
Controls (n=19) 0.002   (0-0.007) 0.84    (0.22-3.95) 0.09   (0.07-0.24) 0.54   (0.31-0.74)
Patients Eos+ (n=16) 0.007   (0-0.010) 0.53    (0.35-6.18)# 0.15   (0.08-0.80)# 1.26   (0.92-1.45)*
Patients Eos- (n=8) 0.011   (0.008-0.015)* 23.17  (2.25-68.07)* 0.74   (0.35-2.84)* 0.54   (0.19-0.87)
Patients Re-op+ (n=9) 0.005   (0-0.009)# 0.38    (0.04-2.58)# 0.09   (0.06-0.15)# 0.98   (0.38-1.27)
Patients Re-op- (n=15) 0.010   (0.007-0.017)* 5.31    (1.21-36.80)* 0.69   (0.31-3.21)* 1.19   (0.72-1.45)*
* p<0.05 in comparison to controls
# p<0.05 Eos+ in comparison to Eos- and Re-op+ to Re-op-  
Table 4. The median and 25-75 interquartile range of MMP/TIMP-1 molar ratio in 
controls; in CRSwNP patients with tissue eosinophilia (Eos+) and without it (Eos-); and 
in same patients re-operated on during 3-year-period after initial operation (Re-op+) and 
not re-operated on (Re-op-) 
MMP-7/TIMP-1 MMP-8/TIMP-1 MMP-9/TIMP-1
Controls (n=19) 0.002   (0-0.018) 1.56     (0.80-7.46) 0.22   (0.10-0.67)
Patients Eos+ (n=16) 0.006   (0-0.009) 0.73     (0.29-5.60)# 0.38   (0.11-1.12)#
Patients Eos- (n=8) 0.020   (0.012-0.1) 54.89   (20.83-75.41)* 2.97   (1.83-4.26)*
Patients Re-op+ (n=9) 0.004   (0-0.006) 0.45     (0.26-6.76)# 0.12   (0.09-0.70)#
Patients Re-op- (n=15) 0.010   (0.005-0.046) 16.12   (0.93-54.89) 1.50   (0.62-3.49)*
* p<0.05 in comparison to controls
# p<0.05 Eos+ in comparison to Eos- and Re-op+ to Re-op-  
eosinophil-positive CRSwNP patients and 19 controls, whereas in the eosinophil-
positive patients these parameters were at the same level compared to controls 
(Table 3 and 4). Furthermore, there was a statistically significant difference in the 
median concentration of MMP-7, but not in MMP-7/TIMP-1 ratio, in eosinophil-
negative patients compared to controls. However, the MMP-7 concentrations were 
overall very low (IQR 0·008-0·015 vs. 0-0.007 pmol/mL). 
Nine patients were re-operated on during the three-year period after the initial 
operation. Eight of these nine patients had tissue eosinophilia, but there was no 
statistically significant difference in risk for re-operation between eosinophilic and 
non-eosinophilic CRSwNP patients (P=0.17). However, in nine re-operated 
patients the levels of MMP-7, MMP-8 and MMP-9 together with the MMP-
8/TIMP-1 and MMP-9/TIMP-1 molar ratios were significantly lower when 
compared with 15 patients who did not need re-operation (Table 3 and 4). Among 
eosinophil-positive CRSwNP patients the eight re-operated patients, in relation to 
eight non re-operated subjects, had lower MMP-8 (median 0.38 pmol/mL, IQR 
0.03-2.63 pmol/mL vs. median 2.17 pmol/mL, IQR 0.47-9.86 pmol/mL), MMP-9 
(median 0.07 pmol/mL, IQR 0.06-0.14 pmol/mL vs. median 0.91 pmol/mL, IQR 
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0.31-2.26 pmol/mL), MMP-8/TIMP-1 ratio (median 0.36, IQR 0.20-3.65 vs. 
median 1.86, IQR 0.37-6.73) and MMP-9/TIMP-1 ratio (median 0.11, IQR 0.08-
0.33 vs. 0.88, IQR 0.43-1.96). The differences in MMP-9 concentration and MMP-
9/TIMP-1 ratio were significant (P<0.01 and P<0.05, respectively). 
3.2. Molecular forms and degree of activation of MMP-8 and MMP-9      
(III, IV) 
Western immunoblotting analysis revealed both isoforms of MMP-8 at 
approximately 70 to 80 kDa representing activated and latent forms of neutrophil 
(PMN)-type MMP-8 and two species at approximately 45-50 to 55-60 kDa 
representing activated and latent forms of non-PMN-type MMP-8 derived from the 
mesenchymal cells in patient samples. Mainly the mesenchymal-type MMP-8 was 
converted to active forms except in six patients, who had also detectable 
immunoreactivity of active PMN-type MMP-8. There was no difference in the 
degree of MMP-8 activation between the eosinophil-positive and eosinophil-
negative patient. In re-operated patients the proportion of latent mesenchymal 
MMP-8 isoform, but not active mesenchymal isoform, was significantly lower than 
in those patients who were not re-operated (median 2.0%, IQR 0-4.1% vs. median 
8.7%, IQR 6.2-9.9%, P=0.02). Also higher levels of >90 kDa high molecular size 
MMP-8 species were detected in samples from CRSwNP patients in relation to 
controls. A latent form of PMN-type MMP-8 was major MMP-8 species observed 
in NALs from controls. 
Gelatin zymography revealed three forms of MMP-9 at approximately 120 kDa, 92 
kDa and 82 kDa representing MMP-9-NGAL complex and latent and activated 
forms of MMP-9, respectively. All MMP-9 forms were detected in both patient 
groups and controls. In controls these forms were seen in equal proportions 
(median 33.0%, 33.7%, and 32.4%), whereas in patients the level of latent form 
was increased and active form decreased in relation to controls (median all patients 
33.7%, 50.2% and 14.1%). There was no significant difference in the distribution 
of MMP-9 forms between the eosinophil-positive patients and eosinophil-negative 
patients, neither between the re-operated patients and those who were not. 
3.3. Correlation between MMP-8 and cytokines (III) 
The mesenchymal-type MMP-8 isoform but not PMN-type MMP-8 isoform was 
converted to active form as the IL-8 concentration increased in CRSwNP patients. 
A significant correlation (r = 0.630, P<0.05) between IL-8 and the proportion of the 
activated form of mesenchymal MMP-8 immunoreactivity was observed. The other 
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studied parameters (IL-8 or TNF-α vs. MMP-8 concentration; IL-8 or TNF-α vs. 
PMN-type MMP-8 immunoreactivity; TNF-α vs. the proportion of the activated 
form of mesenchymal MMP-8 immunoreactivity) did not show a significant 
correlation. 
3.4. Correlation between MMPs and TIMP-1 (IV) 
A significant correlation (r = 0.560, P<0.01) between MMP-8 and MMP-9 was 
observed. The other studied parameters (TIMP-1 vs. MMP-7, MMP-8 or MMP-9; 




1. Patient characteristics 
Patients were representative of typical CRSwNP patients. Fifty % reported allergic 
rhinitis, 57% had asthma and 29% of the asthmatic patients had ASA intolerance, 
which concurs with previous reports.122,272,282,283,294 In the general population in 
Finland the incidence of allergic rhinitis is approximately 15-20% and the 
incidence of asthma is 2-6%.120,133,263 Also the incidence of ASA intolerance among 
asthmatic CRSwNP patients was markedly higher than the reported incidence of 
approximately 9% in asthmatic patients in Finland.133 In this study tissue 
eosinophilia was found in 19 patients (63%), of whom 13 subjects had also asthma 
and four subjects  had ASA intolerance, whereas in the literature 80-90% of 
CRSwNP patients are described to have eosinophilic inflammation.142 Secretion 
eosinophilia was found only in eight patients. Eosinophil staining was done on the 
NAL sample, and it is possible that NAL fluid does not contain a sufficient 
concentration of cells and mucus from sinus cavity to detect secretion eosinophilia. 
In the present study three patients had specific IgG subclass deficiency and one 
patient had both IgG subclass and IgM deficiencies. In several studies a high 
incidence of immunodeficiency among CRS patients has been demonstrated, with 
the IgG subclass deficiency being the most common immune defect in up to over 
30% of CRS patients.55,194,265 Our results suggest also that the polypoid form of 
CRS is associated with immunodeficiency. However, the small number of patients 
and patient selection have an influence on the results, as well as the fact that the 
patients entering this study were not tested systemically for immune dysfunction. 
CRSwNP is known to have a high frequency of recurrence: 63% of the patients in 
the present study had been operated on earlier and similar numbers have also been 
described in literature.91,122,158,281 In a long-term follow up study of nasal polyps the 
ASA intolerant patients had the highest frequency of recurrence and they usually 
needed re-operation and medication more often than patients with atopic allergy or 
intrinsic allergy-like disease.318 The high recurrence frequency in ASA intolerant 
patients was also seen in the present study. All the patients with ASA intolerance 
had been operated on prevuously and four of these five patients had had several 
operations. Seventy-five % of asthmatic patients without ASA intolerance had had 
a previous operation compared to 54% of non-asthmatic patients. Moreover, in the 
three year period after the initial operation, nine out of 24 patients enrolled to the 
study IV (38%) were re-operated. Of re-operated patients, eight subjects had tissue 
eosinophilia, which is usually associated with poorer prognosis in CRSwNP.99 
Moreover, also seven re-operated patients were asthmatic. The number of patients 
is too small to make further conclusions but CRSwNS associated with asthma and 
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no ASA intolerance could have a poorer prognosis than CRSwNP in non-asthmatic 
patients. Every patient with immunodeficiency had been operated on earlier and 
three of these patients were also re-operated during follow-up period. Thus, the risk 
for recurrent operations appears to be associated with tissue eosinophilia, asthma, 
ASA intolerance and immunodeficiency. On the other hand, tissue eosinophilia was 
strongly associated with asthma and ASA intolerance, and so this may reflect a 
common pathophysiologic mechanism in CRSwNP patients with systemic and 
more active disease. 
2. Microbiology of chronic rhinosinusitis with nasal polyposis 
2.1. Bacteria 
The bacteria culture results were similar to those of previous studies.38,122,147,264,326 
Staphylococcus aureus and coagulase-negative Staphylococci were the two most 
common isolates in both the control group and the patient group. Pseudomonas, 
which is reported to be associated with CRS, was not recovered from any patient or 
control sample.209. However, in the patient group other bacterial species, which are 
rarely discovered from healthy noses or acute community acquired rhinosinusitis, 
including Klebsiella, Escherichia coli and Proteus, were isolated. The 
polymicrobial aetiology of CRS, consisting particularly of aerobic and anaerobic 
beta-lactamase-producing bacteria, is highlighted in some studies.27,41 Beta-
lactamase-producing bacteria were found in the present study, but their pathogenity 
in CRS is unknown. The same bacteria are also the main components of the normal 
nasal flora.147,264 However, it is hypothesized that the normal nasal flora may be the 
normal flora solely under healthy conditions.27 The only anaerobic bacteria isolated 
from three patients’ samples and one control sample taken in September was 
Propionibacterium acnes. Aral and colleaques found anaerobes in 14.2% of 
maxillary sinus aspirates taken during ESS whereas only aerobes grew in the 
ethmoid sinus samples and nose swap samples from the same patients.7 Samples 
taken “deeper” inside the nose could favour anaerobes, as well as the changes in the 
sinus microenvironment during chronic rhinosinusitis, such as impaired ventilation 
and reduced oxygen levels.40 On the other hand anaerobic bacteria, especially 
Propionibacterium species are found in up to 100% of nasal cavities of healthy 
subjects.147 
Bacteria may be implicated in CRS by other mechanisms than those causing 
chronic infection.  Several bacterial species implicated in chronic rhinosinusitis are 
potent inducers of IgE pointing to a possible allergic mechanism.27 One of the most 
likely candidates in CRSwNP is superantigen producing strains of Staphylococcus 
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aureus, which are supposed to cause eosinophilic inflammation of the sinus mucosa 
in genetically susceptible hosts.12,266 Specific IgE to Staphylococcus aureus 
enterotoxins A and B has been demonstrated in 50% of altogether 20 patients with 
eosinophilic nasal polyposis.12 The presence of Staphylococcus aureus enterotoxin 
specific IgE associated with higher levels of total serum IgE, more severe local 
disease and increased incidence of systemic manifestations (asthma), suggesting 
that superantigens can impact on disease severity. In the present study, eight of ten 
patients with Staphylococcus aureus had been operated on at least once earlier, but 
the prevalence of Staphylococcus aureus was about the same in the control group. 
Longer courses of the disease and several operations could also have influenced the 
normal nasal flora, which could favour Staphylococcus aureus. Moreover, no 
classification of different types of Staphylococcus aureus was performed in the 
present study, making it impossible to estimate the superantigen theory in the 
persistence of disease.  
2.2. Fungi 
Seven patients were diagnosed to have possible fungal rhinosinusitis. The criteria 
of sinus mycetoma were met in three patients. In two of them there were fungal 
hyphae consistent with Aspergillus in biopsy and in one patient the fungal culture 
was positive for Aspergillus fumigatus. The remaining four patients were 
considered as having AFRS-like syndrome, because the diagnostic criteria in AFRS 
vary and the atopic status of patients was not analyzed. No invasive fungal 
infections were discovered. The fungi were present either in the direct microscopy 
of the sinus mucus or in the histological examination, representing thus a real 
fungal finding, not a contamination of a sample. Culture was positive in only two 
patients, who had also fungal hyphae present in the fungal staining of sinus mucus. 
This reflects the poor viability of the fungi and concurs with the estimation that 
only 20-40% of fungal infections are culture positive.110 Based on this finding it 
can be concluded that fungal staining of mucus as well as histological samples 
stained with specific fungal staining are needed to detect fungi.  
The occurrence of fungal rhinosinusitis in this study (23%) is high when compared 
to the estimated 5-10% prevalence in the literature.110,190 However, an equal 
prevalence of fungal positive findings was found in a study of 117 
immunocompetent patients having CRS together with a presence of granulomatous 
and friable material within the sinus in endoscopy.317 In that study 25.7% of the 
surgical specimens were positive for fungi with Aspergillus species being the most 
prevalent fungal genera. The authors concluded that the results represent a fungal 
colonization of the paranasal sinuses instead of a mycosis. On the other hand, their 
results may indicate that when the typical findings are present, there is strong 
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possibility of fungal infection. A much higher incidence of fungal findings, 
exceeding over 90 %, in the adult CRS patients has been found in some other 
recent studies.32,45,246 It is not known whether or not the fungi can exist in the 
sinuses without causing a disease. However, the absence of any difference between 
the patient and the control fungal culture results in the nasal swabs and NAL 
samples simply reflects the fungal colonization of the nose.32,45,50,246 This has been 
demonstrated also in a study of 30 neonates, whose nasal mucus samples yielded 
positive fungal culture in 15% on the fourth day postpartum and the number 
increased to 94% in four months.174 In the present study five of seven fungus 
positive patients (71%) were operated on earlier. That does not differ significantly 
from the average 63% of all patients in this study. In our view the presence of fungi 
does not explain the chronic course of CRSwNP. However, it should be kept on 
mind, that some patients with typical clinical picture of CRSwNP may actually 
have fungal rhinosinusitis, in which case early operative treatment is the treatment-
of-choice.82-84 
2.3. Seasonal variation in controls 
The presence of two common airborne outdoor fungal species, namely 
Cladosporium and Alternaria, was clearly seen in the autumn samples, whereas 
every sample taken in January was negative for fungi. These results reflect the 
fungal spores in the patient’s outdoor environment, as the same fungal species were 
also seen in high levels in the air at the same time. This theory is supported further 
by the finding that the most common airborne indoor fungal genera, i.e. 
Penicillium, Aspergillus, Cladosporium, Alternaria and Aureobacidium, are also 
the most prevalent isolates in NAL samples from CRS patients and controls in 
several studies.32,45,53,246 Moreover, Cladosporium spp., Alternaria spp. and 
Aureobacidium spp. showed a significant seasonal fluctuation with the maxima in 
late summer/early autumn.45 In our study the similar seasonal variation was not 
seen in the patient samples. The patients’ samples were collected directly from the 
sinuses, which probably explain the difference. The paranasal sinuses are not so 
easily accessible by fungal spores in the inhaled air, especially if the spores are big 
like those of Alternaria and Cladosporium. The results of Buzina and colleagues 
support this theory.45 In their study 91.3% of 104 mucus samples obtained by NAL 
method from CRS patients yielded positive fungal culture compared to 84.0% of 
106 samples obtained during ESS. However, the occurrence of some taxa, 
Cladosporium for example, was significantly higher in NAL samples (65.2% in 
controls and 42.3% in patients) than in samples collected from the sinuses during 
surgery (20.8%). The bacterial culture results in the controls show that the normal 
nasal bacterial flora varies according to time. More positive bacterial cultures grew 
in the autumn samples, but the bacterial species found did not differ much from the 
Discussion 71
winter results or the species isolated from the patient samples. It was mainly the 
increase in the presence of the coagulase negative staphylococci, which explains 
the increase in the number of positive bacterial cultures in autumn. 
3. Impact of moisture exposure on chronic rhinosinusitis with nasal 
polyposis 
The presence of moisture has become a popular explanation for different 
respiratory and general symptoms. This together with the need of patients to find a 
cause for illness might lead to an overestimation of the association between 
moisture problems and the symptoms. In the present study the patients had 
objective findings of CRSwNP, which is probably less sensitive to reporting bias 
compared to subjective estimation of symptoms. Moreover, patients reported 
mainly obvious water damage, visible mould or repairs done due to the moisture 
damage, which are clear signs, not only suspicion of moisture damage. An 
association between fungal rhinosinusitis or CRSwNP and exposure to dampness 
was not apparent in the present study. Altogether 46% of patients reported exposure 
to moisture at home or at work in this study. It is high compared to the 15-23% 
prevalence of damp/mouldy homes in two other Finnish questionnaire 
surveys.161,241 The higher prevalence of reported moisture problems may be partly 
due to the fact that we estimated exposure to moisture both at home and at work. 
Moreover, the last three years instead of the last one year typically assessed in 
questionnaire surveys of this nature were evaluated in this study. However, the 
found prevalence is comparable to another Finnish study where a random sample of 
310 houses was studied.167 A moisture problem was observed by a surveyor in 52% 
of the houses, whereas a mould problem was reported by the occupants in 27%. 
In this study three out of six patients with fungal rhinosinusitis reported moisture 
exposure, which is in accordance with the 46 % prevalence of moisture damage in 
patients altogether. The variants of fungal rhinosinusitis were distributed evenly: 
one mycetoma patient and two with an AFRS-like syndrome in both exposed and 
non-exposed patients. There was a marginally higher occurrence of previous nasal 
or sinus operations among the patients exposed to moisture (77% vs. 60%), but 
repeated operations were reported equally suggesting that there was not a 
significant difference in the persistence of the disease between the groups. Tissue 
invasion by indoor moulds is evidently rare except in persons who are severely 
immunocompromised.128,316 However, there may be alternative mechanisms to 
explain how moisture, mould growth or possibly other factors co-existing in a 
damp environment might cause chronic mucosal irritation and/or impaired 
mucociliary clearance leading to the development of CRS. For example, up-
regulation of inflammatory mediators due to the environmental exposure may also 
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alter the inflammatory cascade in the nasal and sinus mucosa. For example, nitric 
oxide favours the expression of Th2 cells by being less inhibitory to Th2 cells than 
Th1 cells.155 The elevated levels of nitric oxide have been detected in NALs from 
the staff working in a mould-contaminated school, whereas there is evidence of 
Th2 cell involvement in allergic as well as non-allergic rhinosinusitis.16,125,137,249  
The prevalence of tissue eosinophilia was higher in exposed group (75% vs. 53%). 
The increased concentrations of ECP, a marker of the eosinophil activation, have 
been detected in NAL samples from people working in damp office building and 
from subjects exposed to formaldehyde, nitrogen dioxide, and Aspergillus 
spp.218,329 No mucosal biopsies from the nose or the sinuses were examined in these 
studies, but these findings are still interesting, because the eosinophilic 
inflammation is considered as a key event in the pathogenesis of CRSwNP.13,99,172 
Moreover, the presence of tissue eosinophilia in CRS is associated with more 
severe disease and an increased need for repeated operations.99 These results from 
previous studies may provide a possible link between environmental exposure and 
chronic inflammation of the nasal mucosa. Thus, some connection between 
environmental exposure and CRSwNP may exist, although we did not find an 
association between them.  
4. MMPs and TIMP-1 in chronic rhinosinusitis with nasal polyposis 
There are only very limited data concerning MMPs in CRS, but MMPs have been 
studied extensively in lower airway diseases. The characteristics of inflammation 
are rather similar in CRSwNP and asthma, and thus they may represent, at least in 
part, a different clinical picture of the same pathophysiological process.30,196,245 
Thus, the results from our studies are discussed in respect to previous findings in 
CRS as well as in lower airway physiology and pathology, especially in relation to 
findings in asthma. Along with the expression of MMPs the MMP/TIMP-1 molar 
ratio is an important aspect when estimating MMP functions and roles in disease 
pathogenesis, as the balance between them is though to be critical factor in 
regulating the breakdown of connective tissues and the immune reactions by 
MMPs. 
In this study the levels of MMP-7 in eosinophil-negative CRSwNP patients were 
statistically significantly elevated in relation to controls, but comparable with 
eosinophil-positive patients. However, the MMP-7 concentrations were overall 
very low (IQR 0·008-0·015 pmol/mL in eosinophil-negative patients) and did not 
exceed TIMP-1 concentrations and are thus probably of minor clinical and 
pathophysiological importance. MMP-7 is one of the few MMPs which are 
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constitutively expressed in non-injured, normal epithelium, where it is considered 
to contribute to tissue homeostasis and innate immunity.233,341 The elevated MMP-7 
levels have been found also in CRSwNP.336 In particular, the inflammatory cells 
stained positive for MMP-7, as well as for MMP-9 were found inside the 
pseudocysts, pointing to their possible degradative function in nasal polyposis 
pathogenesis.336 In the present study MMP-7 was measured from sinus mucus/NAL 
samples, which could explain the difference from the previous results. The spatial 
distribution of MMP-7 is distinct in repair and inflammatory functions, as the 
wound induced MMP-7 is released basally towards the underlying matrix 
compared to its release to airway lumen away from matrix in other functions.233 On 
the other hand, bacterial exposure in mucosal epithelial tissues induces 25-50 fold 
increase in expression of MMP-7.187 Since no such increase was seen in the present 
study, it seemingly provides more evidence of non-infectious etiology of CRSwNP. 
Concurrent with previous reports, we observed a significant increase in MMP-9 
concentration in sinus mucus from CRSwNP patients. Moreover, the patients 
without tissue eosinophilia in sinus mucosal biopsy had significantly elevated 
levels of MMP-9 when compared to eosinophil-positive patients and controls, 
whereas in eosinophil-positive patients these parameters were at the same level 
compared to controls. A similar distribution was seen in the MMP-9/TIMP-1 molar 
ratio, with the median ratio in eosinophil-negative patients, eosinophil-positive 
patients and controls being 2.97, 0.38 and 0.22, respectively. There was no 
difference in the degree of activation of MMP-9 between patients groups. In the 
previous studies the elevated levels of MMP-9 and TIMP-1 has been found in 
CRSsNP, whereas in nasal polyposis MMP-9, but not TIMP-1, was up-
regulated.180,336 TIMP-1 is considered to have fibrogenic properties resulting from 
inhibition of MMP-9 and promotion of growth of fibroblasts and myofibroblasts 
seen also in nasal polyp tissue in contrast to normal nasal epithelium.131,332 The 
TIMP-1/MMP-9 imbalance could thus lead to pathologic collagen deposition seen 
in CRS and asthma.29,193,284,321 Unfortunately the MMP-9/TIMP-1 molar ratio has 
not been reported in the previous studies, but the up-regulation of TIMP-1 in non-
polypoid form of CRS could explain the prominent fibrosis found in this subgroup, 
but not in CRSwNP.207 On the other hand, depending from the MMP function, lack 
of inhibition of MMPs in nasal polyp tissue could lead to pseudocyst formation by 
tissue destruction. 
These findings considering up-regulated MMP-9 expression in non-eosinophilic 
inflammation were unexpected, since MMP-9 has been implicated in eosinophil 
migration through basement membranes.224 In addition, MMP-9 is produced by 
many cells that accumulate in allergic airway inflammation including eosinophils, 
and MMP-9 gene deletion is associated with impaired transmigration of dendritic 
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cells to the airway lumen and decreased peribronchial eosinophilic 
inflammation.9,48,193,223,320 Tissue eosinophilia in CRS is associated with more 
active disease. In this respect, our results are in contrast to the previous findings 
revealing that MMP-9 expression in the nasal mucosa and its concentration in sinus 
fluid after sinus surgery are linked with poor healing estimated by endoscopy, 
although it did not correlate with edema, fibrosis, or inflammatory cells in tissue.337 
The samples in the present study were collected during operation and the prognosis 
was estimated as a need for re-operation, which may explain the difference. 
Probably the reason for seemingly incongruent results is alterations of MMP 
functions in different disease phases. In vitro studies in Ewing’s sarcoma cell line 
have shown that enhanced MMP-9 expression results in decreased levels of surface 
E-cadherin by mechanism not related to decreased proteolysis of surface E-
cadherin.262 E-cadherin is a cell-surface glycoprotein involved in cell-to-cell 
adhesion and is responsible for the organization, maintenance, and morphogenesis 
of epithelial tissues. Thus, an increase in MMP-9 expression after operation in 
relation to poor outcome may reflect disturbances in tissue repair mechanisms, 
whereas preoperative/intraoperative up-regulation MMP-9 may result from several 
different reasons varying from tissue homeostasis to disease pathogenesis. 
A significant increase in MMP-8 concentration was seen in a subgroup of 
CRSwNP patients entered in the study III in relation to healthy controls. Mainly the 
mesenchymal-type MMP-8 isoform (45-55 kDa) was converted to active forms 
except in two patients, who had detectable immunoreactivity of active 65-75 kDa 
PMN-type MMP-8, perhaps representing the acute exacerbation of CRSwNP. In 
controls instead 80 kDa latent form of PMN-type MMP-8 was major MMP-8 
species observed in NALs. However, in study IV the CRSwNP patients altogether 
did not show enhanced MMP-8 expression relative to controls. The degree of 
MMP-8 activation was similar to that found in study III. When patients in the Study 
IV were divided to two subgroups according to tissue eosinophilia, a clear 
difference in proteolytic pattern was found. As in MMP-9 expression, also MMP-8 
concentration was significantly higher in CRSwNP patients without tissue 
eosinophilia when compared to eosinophil-positive patients and controls. Again, 
there was no statistically significant difference between eosinophil-positive 
CRSwNP patients and controls, nor did the patient groups differ in the molecular 
forms and degree of activation of MMP-8.  
MMP-8 has not previously been studied in CRS with or without nasal polyposis. 
MMP-8 is regarded as playing a central role at sites of matrix, especially type I 
collagen, degradation associated with inflammation.127,228,252 Elevated levels of 
both PMN-type and mesenchymal-type MMP-8 isoforms has been found to be 
converted to active forms in BAL fluid from patients with bronchiectasis, a disease 
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characterized by irreversible tissue injury.253  In asthmatic patients the secreted 
MMP-8 in BAL fluid was converted into active form in steroid naïve or 
uncontrolled severe disease but not in clinically stable disease, nor in healthy 
controls.252 In that study MMP-8 immunoreactivity was detectable especially in the 
bronchial epithelial cells in the areas of injured airway epithelium. In asthmatic 
airways high levels of activated MMP-8 probably indicates more advanced 
destructive and irreversible tissue injury rather than inflammation itself. In this 
respect, it is possible that activation of mesenchymal-type MMP-8 in CRSwNP 
emphasizes repeatedly damaged mucosal epithelial lining as well. In addition, 
differences in both MMP-8 and MMP-9 expression between eosinophilic and non-
eosinophilic CRSwNP suggest that different pathophysiologic mechanisms can be 
involved in these subgroups.   
4.1. Activation of MMP-8 in correlation to increase in IL-8 concentration 
Activation of mesenchymal-type MMP-8 was associated with elevated levels of IL-
8 but not TNF-α. IL-8 is a potent chemoattractant for and inducer of neutrophil 
degranulation, but there is limited data that it can act as a chemoattractant for 
eosinophils in allergic persons.257,335 The sinus mucosal expression of the IL-8 gene 
was increased in patients with chronic rhinosinusitis.257 Moreover, the level of IL-8 
gene expression correlated with the disease severity assessed by sinus CT scores 
and with symptom scores. Interestingly, the incidence of IL-8 gene expression did 
not vary with allergic or asthmatic status, the presence or absence of polyps, or the 
use of corticosteroids. Thus, it is not known if IL-8 expression is actually 
dysregulated in CRS or does it rather represent an innate immune response to sinus 
infection.31  
IL-8 is known to stimulate MMP-8 expression and secretion.314 A significant 
correlation (r = 0.628, P<0.02) between IL-8 and the proportion of the activated 
form of total mesenchymal MMP-8 immunoreactivity was observed in the present 
study. The regulation of MMPs is complex and occurs at different levels including 
gene transcription, mRNA stability, synthesis, secretion, proenzyme activation and 
inhibition by specific and non-specific factors. However, taking into consideration 
the close relationship between the inducer and target, IL-8 and MMP-8 may form a 
pivotal inductive cytokine-proteinase cascade in the pathogenesis of CRSwNP. 
This finding is different from the earlier theory that eosinophil granule proteins 
mediate tissue damage in chronic rhinosinusitis.13,99,129 MMP-8 is not implicated in 
development of eosinophilic inflammation, a major histological hallmark of 
CRSwNP. An IL-8/MMP-8 relationship may, at least in part, explain the 
mechanism of macrolide antibiotics, which has been shown to be as effective as 
prednisolone in chronic rhinosinusitis in long-term, low-dose administration.331 
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Macrolide antibiotics can produce a significant reduction in IL-8 production, which 
subsequently in turn may lead to reduced MMP-8 levels and activation. 
In study III the high prevalence of asthma among the CRS patients was first 
suspected to explain the up-regulation of MMP-8 in the patient group. In contrast to 
that what was expected, the level of MMP-8 expression was lower in asthmatic 
than non-asthmatic patients, although this difference was not statistically 
significant. However, considering the results from study IV, this difference was 
probably due to different proteolytic pattern in eosinophilic and non-eosinophilic 
inflammation, since eosinophilia associated strongly with asthma. Therefore, the 
possible inductive IL-8-MMP-8 cascade in CRSwNP in relation to tissue 
eosinophilia needs to be studied further in larger patient population and in different 
CRS subgroups.   
4.2. The protective role of MMP-8 and MMP-9 in chronic rhinosinusitis 
with nasal polyposis 
We demonstrated enhanced in vivo MMP-8 and MMP-9 expression together with 
increased MMP-8/TIMP-1 and MMP-9/TIMP-1 molar ratios in non-eosinophilic 
chronic rhinosinusitis with nasal polyposis, whereas in eosinophil-positive patients 
these parameters were at the same level compared to controls. Also in patients with 
more active disease, estimated as a need for re-operation during the three-year-
period after initial operation, the levels of MMP-8, MMP-9 and their molar ratios to 
TIMP-1 were significantly lower than in patients who were not re-operated. 
Enhanced and persisting allergen-induced airway inflammation involving increased 
number of eosinophils in MMP-9 deficiency in mice may indicate defensive 
reaction of MMP-9 in lung injury following allergen challenge and especially the 
importance of MMP-9 in its resolution.195 This is in accordance with the known 
function of gelatinases in the transepithelial migration of inflammatory cells, 
including eosinophils, in the bronchial mucosa.67 MMP-2 and MMP-9 regulate the 
formation of transepithelial C-C chemokine gradients, which conduct the 
extravasated inflammatory cells through the pulmonary interstitium and airway 
epithelium to enter the airway lumen, where they are cleared. Lack of MMP-2, 
affecting only eotaxin (CCL11), and MMP-9, affecting eotaxin, CCL7, and CCL17, 
disrupts the normal cell trafficking into the airway lumen and favour their 
accumulation in parenchyma. Thus, by generating several transepithelial 
chemokine gradients, MMP-9 is essentially implicated in the resolution of 
allergic/eosinophilic inflammation. It most likely serves the same function in 
CRSwNP, as also eotaxin is implicated in the accumulation of eosinophils in this 
disease.11,276 
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As in MMP-9, the lack of MMP-8 up-regulation associated with poorer prognostic 
factors in eosinophil-positive patients may indicate defensive role of MMP-8 in 
CRSwNP. Furthermore, in non-eosinophilic CRSwNP patients the MMP-8/TIMP-1 
molar ratio was markedly higher than the MMP-9/TIMP-1 ratio. This difference 
may implicate also more important function of MMP-8 in inflammatory control. 
The functions of MMP-8 in inflammatory disorders are not well established, 
making it impossible to evaluate the possible reciprocal relationship of MMP-8 and 
MMP-9. However, based on previous result, synergic function seems more 
plausible. MMP-8 and MMP-9 deficiencies are both associated with reduced 
inflammatory cell apoptosis and prolonged inflammatory response in allergen-
induced airway inflammation.111,195 Moreover, similar inflammatory features 
consistent with characteristic inflammatory features in CRSwNP, namely enhanced 
levels of Th2 cytokines and eosinophils, have been found both MMP-8 and MMP-9 
knock-out mice in allergen-induced airway inflammation, suggesting synergic 
function of MMP-8 and MMP-9 in the control of Th2 inflammation.111,195 The 
strong positive correlation (r = 0.560, P<0.01) between MMP-8 and MMP-9 in 
patients in the present study provide further evidence of their synergic functions in 
the airway inflammation. In addition, MMP-9 is known to enhance IL-8 activity, 
which in turn may result in the activation of MMP-8, as seen in study III.313 
The possible anti-inflammatory function of MMP-8 and MMP-9 was further 
confirmed, when patients who were re-operated on due to CRSwNP during the 
three-year period after initial operation were compared to not re-operated patients. 
Nine patients were re-operated on, of whom eight had tissue eosinophilia, although 
there was no statistically significant difference in the risk for re-operations between 
the eosinophilic and non-eosinophilic CRSwNP patients. However, significantly 
elevated levels of MMP-8 and MMP-9 concentrations and MMP-8/TIMP-1 and 
MMP-9/TIMP-1 molar ratios were found in patients who did not need re-operation 
in relation to re-operated patients. The lower MMP levels in eosinophilic CRSwNP 
in general do not seem to fully explain the difference between these patient groups, 
since partly similar difference was seen when comparing only eosinophilic 
CRSwNP patients. Also, in this subgroup the re-operated patients, in relation to not 
re-operated subjects, had lower MMP-8 and MMP-9 concentrations along with 
their molar ratios to TIMP, but only MMP-9 values reached statistical significance. 
Thus, it seems that up-regulation of MMPs is needed in reaction to different stimuli 
including perhaps also inflammation or infection in order to prevent prolonged 




I. Microbiological findings do not seem to explain the chronic course of 
CRSwNP. The occurrence of fungal rhinosinusitis in CRSwNP patients 
exceeded the estimated 5-10% prevalence in rhinosinusitis in general, 
implicating association of this CRS subgroup with non-invasive fungal 
infections. The risk for recurrent operations for CRSwNP was associated with 
tissue eosinophilia, asthma, ASA intolerance and immunodeficiency, which 
may present malfunctions in systemic immunologic mechanisms in the 
pathophysiology of CRSwNP. 
II. CRSwNP and fungal rhinosinusitis were not associated with exposure to 
moisture damage at home or in the workplace. Environmental exposure 
reflects to the fungal findings in the nasal cavity. This should be taken into 
account, especially when the NAL samples are used for microbiological 
studies. 
III. MMP-8 expression was upregulated in CRSwNP patients. In particular, the 
mesenchymal-type MMP-8, but not PMN-type MMP-8, was converted to 
active form as the IL-8 concentration increased. TNF-α did not show a 
correlation with MMP-8. The observed IL-8/MMP-8 relationship may form an 
inductive cytokine-proteinase cascade in CRSwNP pathogenesis and may 
provide a target for novel anti-cytokine or anti-collagenase therapies. 
IV. The proteolytic spectrum was different in eosinophilic and non-eosinophilic 
CRSwNP with the up-regulation of MMP-8 and MMP-9, as well as their 
molar ratio to TIMP-1, but not MMP-7, in non-eosinophilic form. This 
difference may reflect differences in pathogenesis in these subgroups and 
suggest a MMP-dependent mechanism in eosinophil-accumulation in 
CRSwNP. Eosinophilia in CRS is associated with more extensive disease and 
increased need for repeated operations, thus the lack of MMP up-regulation in 
eosinophilic CRSwNP in reaction to inflammatory stimuli may also indicate 
synergic protective/anti-inflammatory functions of MMP-8 and MMP-9 in 
CRSwNP. Similar difference was observed when re-operated patients were 
compared to patients who did not need re-operation. As MMP inhibitors are 
proposed to be of potential therapeutic value in chronic respiratory tract 
diseases, the better and more detailed understanding of MMP functions in 
inflammatory conditions is needed. 
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